Research library
Master Citation List
Every study cited on Peptide Initiative, organized by page. Numbers match the inline citations you see in the content; each entry lists the sections where it is cited and links to the original source.
138 pages
Peptide Profiles 138
5-Amino-1MQ5 studies
View page[1]Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice
Neelakantan H, Vance V, Wetzel MD, Wang HL, McHardy SF, Finnerty CC, Hommel JD, Watowich SJ · 2018
Cited in: Dosing · adjustment, Is this right for me, Dosing, Effectiveness · signs, FAQ, How to use, Safety, Effectiveness · how it works, Safety · side effects, Effectiveness · timeline, Dosing · timing, Effectiveness · troubleshooting
View study[2]Nicotinamide N-methyltransferase Inhibition Mitigates Obesity-Related Metabolic Dysfunctions
Babula JJ, Bui D, Stevenson HL, Watowich SJ, Neelakantan H · 2024
Cited in: Dosing · adjustment, Is this right for me, Dosing, Effectiveness · signs, FAQ, How to use, Safety, Effectiveness · how it works, Safety · side effects, Effectiveness · timeline, Safety · when to stop
View study[3]Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice
Dimet-Wiley A, Wu Q, Wiley JT, Eswar A, Neelakantan H, Savidge T, Watowich SJ · 2022
Cited in: FAQ
View study[4]Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome
Sun WD, Zhu XJ, Li JJ, et al. · 2024
Cited in: Is this right for me, FAQ, Effectiveness · how it works
View study[5]PubChem Compound Summary: 5-Amino-1-methylquinolinium (CID 950107)
National Center for Biotechnology Information (NCBI) · 2024
View studyAbarelix4 studies
View page[1]GnRH Peptide Antagonist: Comparative Analysis of Chemistry and Formulation with Implications for Clinical Safety and Efficacy
Patel S, Saxena B, Mehta P · 2024
View study[2][3]Gonadotropin-releasing hormone: an update review of the antagonists versus agonists
Van Poppel H, Klotz L · 2012
View study[4]Plenaxis (abarelix for injectable suspension) FDA prescribing information / label
U.S. Food and Drug Administration · 2003
Cited in: Dosing
View studyAcetyl Hexapeptide-3 (Argireline)5 studies
View page[1]The anti-wrinkle efficacy of argireline in Chinese subjects: a randomized, placebo-controlled study
Wang Y, et al. · 2013
Cited in: Dosing
View study[2]The anti-wrinkle efficacy of synthetic hexapeptide (Argireline) in Chinese subjects
Wang Y, et al. · 2013
Cited in: Dosing
View study[3][4]A synthetic hexapeptide (Argireline) with antiwrinkle activity
Blanes-Mira C, et al. · 2002
View study[5]The study of cellular cytotoxicity of argireline - an anti-aging peptide
Grosicki M, et al. · 2014
View studyAdipotide4 studies
View page[1]Reversal of obesity by targeted ablation of adipose tissue
Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W · 2004
View study[2]A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys
Barnhart KF, Christianson DR, Hanley PW, et al. · 2011
Cited in: Dosing
View study[3]Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma
Kolonin MG, Pasqualini R, Arap W · 2011
View study[4]Peptide Designed to Elicit Apoptosis in Adipose Tissue Endothelium Reduces Food Intake and Body Weight
Kim DH, Woods SC, Seeley RJ · 2010
View studyAdrenomedullin5 studies
View page[1]Early Use of Innovative Biomarkers Such as Mid-Regional Pro-Adrenomedullin and SeptiCyte RAPID in Post-Cardiac Surgery Patients: Pilot Case Series
Risso C, Vay L, Sciascia F · 2025
View study[2]The Role of Adrenomedullin as a Predictive Marker of the Risk of Death and Adverse Clinical Events: A Review of the Literature
Sacco MA, Gualtieri S, Cordasco F · 2024
View study[3]Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma
Kitamura K, Kangawa K, Kawamoto M, et al. · 1993
View study[4]Adrenomedullin for steroid-resistant ulcerative colitis: a randomized, double-blind, placebo-controlled phase-2a clinical trial
Ashizuka S, Kuroki M, Yamato T, et al. · 2021
Cited in: Dosing
View study[5]Safety, Tolerability, and Pharmacokinetics of Adrenomedullin in Healthy Males: A Randomized, Double-Blind, Phase 1 Clinical Trial
Kita T, Kaji Y, Kitamura K · 2020
Cited in: Dosing
View studyAlexamorelin3 studies
View page[1]Endocrine activities of alexamorelin (Ala-His-d-2-methyl-Trp-Ala-Trp-d-Phe-Lys-NH2), a synthetic GH secretagogue, in humans
Broglio F, Benso A, Gottero C, et al. · 2000
Cited in: Dosing
View study[2]Identification of alexamorelin consumption biomarkers using human hepatocyte incubations and high-resolution mass spectrometry
Pobee E, Daziani G, Gameli PS · 2025
View study[3]Orally active growth hormone secretagogues: state of the art and clinical perspectives
Ghigo E, Arvat E, Camanni F · 1998
Cited in: Dosing
View studyAngiotensin (1-7)5 studies
View page[1]The joint-local renin-angiotensin system in rheumatoid arthritis and osteoarthritis: mechanistic evidence, disease-specific patterns, and translational perspectives
Bilgin E, et al. · 2026
View study[2]Dual Inhibition of the Renin-Angiotensin-Aldosterone System and Sodium-Glucose Cotransporter-2: Mechanistic and Clinical Evidence for Cardiorenal Protection
Aazar RFM, et al. · 2026
View study[3]Exogenous hydrogen sulfide inhibits the progression of vascular dysfunction and hypertension mediated by the renin-angiotensin system in chronic kidney disease
Tapia-Martínez JA, et al. · 2026
View study[4]Pharmacodynamic stimulation of thrombogenesis by angiotensin (1-7) in recurrent ovarian cancer patients receiving gemcitabine and platinum-based chemotherapy
Pham H, Schwartz BM, Delmore JE, et al. · 2013
Cited in: Dosing
View study[5]A randomized, placebo-controlled, double-blinded pilot study of angiotensin 1-7 (TXA-127) for the treatment of severe COVID-19
Self WH, Shotwell MS, Gibbs KW, et al. · 2022
Cited in: Dosing
View studyAOD-96045 studies
View page[1]Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone
Ng FM et al. · 2000
Cited in: Dosing
View study[2]Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment
Heffernan MA et al. · 2001
View study[3]The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice
Heffernan M et al. · 2001
View study[4]Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model
Kwon DR et al. · 2015
View study[5]The effect of AOD9604 on weight loss in obese adults: results of a randomized, double-blind, placebo-controlled, multicenter study
Metabolic Pharmaceuticals; Stier H, et al. · 2007
Cited in: Dosing
View studyApelin-134 studies
View page[1]Exogenous [Pyr(1)]apelin-13 prevents bupivacaine-induced cardiotoxicity via the apelin (APJ) receptor
Chen C, Zhao S, Chen Z · 2025
View study[2]A Metabolically Stable Apelin-13 Analog Acting as a Potent I(To) Potassium Current Blocker with Potential Benefits for Brugada Syndrome
Contreras Vite JA, Tiffinger A, Théroux L · 2025
View study[3]Apelin/APJ signaling in IGF-1-induced acute mitochondrial and antioxidant effects in spontaneously hypertensive rat myocardium
Yeves AM, Godoy Coto J, Pereyra EV · 2024
View study[4]Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure
Japp AG, Cruden NL, Barnes G, et al. · 2010
Cited in: Dosing
View studyARA-290 (Cibinetide)6 studies
View page[1]ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes
Brines M, et al. · 2015
Cited in: Dosing
View study[2]Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain
Culver DA, et al. · 2017
Cited in: Dosing
View study[3]Corneal nerve fiber size adds utility to the diagnosis and assessment of therapeutic response in patients with small fiber neuropathy
Brines M, et al. · 2018
View study[4]Erythropoietin-derived nonerythropoietic peptide ameliorates experimental autoimmune neuritis by inflammation suppression and tissue protection
Liu Y, et al. · 2014
View study[5][6]Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study
Heij L, Niesters M, Swartjes M, et al. · 2012
Cited in: Dosing
View studyBestatin (Ubenimex)5 studies
View page[1]Ubenimex (Bestatin): Immunomodulator with antitumor activity — overview of clinical studies
Umezawa H, Ishizuka M, Aoyagi T · 1986
Cited in: Dosing
View study[2]Effect of bestatin on natural killer cell activity and cell-mediated immunity in leukemia patients
Ota K, Kurita S, Makino N · 1992
View study[3]Bestatin as an immunomodulatory agent: effects on bone marrow recovery and T-cell subset populations
Abe F, Shibuya K, Uchida M · 1990
View study[4]Randomized controlled trial of bestatin maintenance therapy in acute non-lymphocytic leukemia
Hirata Y, Tanimoto M, Ogawa Y · 1991
Cited in: Dosing
View study[5]Leukotriene A4 hydrolase inhibition by bestatin: implications for pulmonary arterial hypertension
Tian W, Jiang X, Tamosiuniene R · 2013
View studyBPC-1573 studies
Buserelin5 studies
View page[1]An improved use of buserelin in ovarian stimulation for in-vitro fertilization
PubMed Central · 1990
View study[2]Gonadotropin-releasing hormone agonists in prostate cancer: A comparative review of efficacy and safety
Raja T, Sud R, Addla S · 2022
View study[3]Cardiovascular adverse events-related to GnRH agonists and GnRH antagonists: analysis of real-life data from Eudra-Vigilance and FDA databases
Cicione A, Nacchia A, Guercio A · 2023
View study[4]Adverse event profile differences among long-acting gonadotropin-releasing hormone analogs: A real-world, pharmacovigilance study
Chen Y, Lu W, Liao R · 2025
View study[5]Product Monograph: SUPREFACT (buserelin acetate) injection and nasal solution, and SUPREFACT DEPOT implant
Sanofi-aventis Canada Inc. · 2015
Cited in: Dosing
View studyCagrilintide5 studies
View page[1]Once-weekly cagrilintide for weight management in people with overweight and obesity
Lau DCW et al. · 2021
Cited in: Dosing
View study[2]Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide
Enebo LB et al. · 2021
View study[3]Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
Garvey WT et al. · 2025
View study[4][5]Capromorelin3 studies
View page[1]Effects of an oral growth hormone secretagogue (capromorelin) in older adults
White HK, Petrie CD, Landschulz W, et al. · 2009
Cited in: Dosing
View study[2]Efficacy and safety of capromorelin (Elura) for weight management in cats with chronic kidney disease: a randomized, double-blind, placebo-controlled trial
Zollers B, et al. · 2020
View study[3]Capromorelin acetate as an oral appetite stimulant in companion animals: mechanism, clinical efficacy, and safety profile
Various veterinary researchers · 2021
View studyCartalax5 studies
View page[1]The influence of peptides on the chondrogenic differentiation of human mesenchymal stem cells during replicative aging
Myakisheva SN, Linkova NS, Diatlova AS · 2023
View study[2]Chondrocytes secretory phenotype associated with aging: role in the pathogenesis of osteoarthritis and prospects for peptide bioregulation
Myakisheva SN, Linkova NS, Kozhevnikova EO · 2023
View study[3]Peptide Regulation of Chondrogenic Stem Cell Differentiation
Linkova N, Khavinson V, Diatlova A · 2023
Cited in: Dosing
View study[4]Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides
Ashapkin V, Khavinson V, Shilovsky G · 2020
Cited in: Dosing
View study[5]Tripeptides slow down aging process in renal cell culture
Khavinson VKh, Tarnovskaia SI, Lin'kova NS · 2014
View studyCathelicidin (hCAP-18 / Synthetic Derivatives)5 studies
View page[1]The antimicrobial peptide SAAP-148 combats drug-resistant bacteria and biofilms
de Breij A, Riool M, Cordfunke RA · 2018
View study[2]SAAP-148 Eradicates MRSA Persisters Within Mature Biofilm Models Simulating Prosthetic Joint Infection
Dijksteel GS, Ulrich MMW, Middelkoop E · 2019
View study[3]Cathelicidin antimicrobial peptides in the treatment of infectious diseases and their clinical potential
Mookherjee N, Anderson MA, Haagsman HP · 2020
View study[4]Ototopical drops containing a novel antibacterial synthetic peptide (P60.4Ac/OP-145): safety and efficacy in adults with chronic suppurative otitis media
Peek NFAW, et al. · 2020
Cited in: Dosing
View study[5]Vitamin D-mediated cathelicidin expression: innate immunity meets antimicrobial defense
Wang TT, Nestel FP, Bourdeau V · 2004
View studyCerebrolysin7 studies
View page[1]Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use
Gavrilova SI, Alvarez A · 2021
View study[2]Role and Impact of Cerebrolysin for Ischemic Stroke Care
Mureșanu DF, Livinț Popa L, Chira D et al. · 2022
View study[3]Cerebrolysin in Patients with Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis
Kojder K, Jarosz K, Bosiacki M et al. · 2023
View study[4]Neuroprotective strategies of cerebrolysin for the treatment of infants with neonatal hypoxic-ischemic encephalopathy
Fiani B, Chacon D, Jarrah R et al. · 2021
View study[5]The possible role of cerebrolysin in the management of vascular dementia: Leveraging concepts
Al-Kuraishy HM, Al-Gareeb AI, Zekry SH et al. · 2025
View study[6]Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial
Guekht AB et al. · 2011
Cited in: Dosing
View study[7]Cerluten6 studies
View page[1]Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer's Disease
Ilina A, Khavinson V, Linkova N · 2022
View study[2]AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism
Khavinson V, Diomede F, Mironova E, Linkova N, Trofimova S, Trubiani O, Caputi S, Sinjari B · 2020
View study[3]Tripeptides Restore the Number of Neuronal Spines under Conditions of In Vitro Modeled Alzheimer's Disease
Kraskovskaya NA, Kukanova EO, Lin'kova NS · 2017
View study[4]Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides
Ashapkin V, Khavinson V, Shilovsky G · 2020
View study[5]Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro
Lin'kova NS, Drobintseva AO, Orlova OA · 2016
View study[6]Cetrorelix6 studies
View page[1]Elagolix Represents a Less Invasive and Cheaper Option Than Injectable GnRH Antagonist for Ovulation Suppression in IVF
Mouanness M, et al. · 2025
View study[2]Progestogens for prevention of luteinising hormone (LH) surge in women undergoing controlled ovarian hyperstimulation
Glujovsky D, et al. · 2023
View study[3]Cocktail treatment by GnRH-antagonist, letrozole, and mifepristone for prevention of ovarian hyperstimulation syndrome
Qi Q, et al. · 2023
View study[4]GnRH antagonist, cetrorelix, for pituitary suppression in modern, patient-friendly assisted reproductive technology
Tur-Kaspa I, et al. · 2009
View study[5]CETROTIDE (cetrorelix acetate for injection) FDA Prescribing Information
2000
Cited in: Dosing
View study[6]Chonluten6 studies
View page[1]Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line
Avolio F, Martinotti S, Khavinson VK · 2022
View study[2]Short Peptides Stimulate Hepatocyte Migration and Proliferation through the CXCR4 Receptor
Khavinson VK, Linkova NS, Diatlova A · 2020
View study[3]Peptide Regulation of Gene Expression and Protein Synthesis in Organotypic Cultures
Khavinson VK, Linkova NS, Kvetnoy IM · 2013
View study[4]Molecular Aspects of Anti-aging Effect of Short Peptides
Khavinson VK, Linkova NS, Tarnovskaya SI · 2021
View study[5][6]Chonluten (bronchopulmonary peptide bioregulator) manufacturer usage instructions
2024
Cited in: Dosing
View studyCJC-1295 (No DAC)20 studies
View page[1]Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Teichman SL et al. · 2006
Cited in: FAQ, Safety, Effectiveness · timeline
View study[2]Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
Ionescu M, Frohman LA · 2006
Cited in: Is this right for me, Safety, Effectiveness · how it works
View study[3]Once-daily administration of CJC-1295 normalizes growth in the GHRH knockout mouse
Alba M, Fintini D, Sagazio A et al. · 2006
View study[4]Activation of the GH/IGF-1 axis by CJC-1295 results in serum protein profile changes in normal adult subjects
Sackmann-Sala L, Ding J, Frohman LA et al. · 2009
View study[5]Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma
Frohman LA, Downs TR, Heimer EP, Felix AM · 1989
Cited in: Effectiveness · how it works
View study[6]Enhanced stability and potency of novel growth hormone-releasing factor (GRF) analogues derived from rodent and human GRF sequences
Campbell RM, Stricker P, Miller R, Bongers J, Liu W, Lambros T, Ahmad M, Felix AM, Heimer EP · 1994
Cited in: Effectiveness · how it works
View study[7]Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog
Jette L et al. · 2005
Cited in: Effectiveness · how it works
View study[8]Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone
Mayo KE · 1992
Cited in: Effectiveness · how it works
View study[9]Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level
Popovic V, Damjanovic S, Micic D, Djurovic M, Dieguez C, Casanueva FF · 1995
Cited in: Is this right for me, Dosing · timing, Effectiveness · troubleshooting
View study[10]Ipamorelin, the first selective growth hormone secretagogue
Raun K, Hansen BS, Johansen NL, et al. · 1998
Cited in: Dosing · timing, Effectiveness · troubleshooting
View study[11]Growth hormone secretion during sleep
Takahashi Y, Kipnis DM, Daughaday WH · 1968
Cited in: Effectiveness · how it works
View study[12]Interrelationships between growth hormone and sleep
Van Cauter E, Copinschi G · 2000
Cited in: Is this right for me, Effectiveness · how it works
View study[13]Effects of growth hormone-releasing hormone and somatostatin on sleep EEG and nocturnal hormone secretion in male controls
Steiger A, Guldner J, Hemmeter U, Rothe B, Wiedemann K, Holsboer F · 1992
Cited in: Is this right for me, Hero
View study[14]Arginine abolishes the inhibitory effect of glucose on the growth hormone response to growth hormone-releasing hormone in man
Ghigo E, Miola C, Aimaretti G, Valente F, Procopio M, Arvat E, Yin-Zhang W, Camanni F · 1992
Cited in: Effectiveness · troubleshooting
View study[15]Evidence for an inhibitory effect of physiological levels of insulin on the growth hormone (GH) response to GH-releasing hormone in healthy subjects
Lanzi R, Manzoni MF, Andreotti AC, Malighetti ME, Bianchi E, Sereni LP, Caumo A, Luzi L, Pontiroli AE · 1997
Cited in: FAQ
View study[16]Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men
Iranmanesh A, Lizarralde G, Veldhuis JD · 1991
Cited in: Is this right for me, FAQ
View study[17]Effects of human growth hormone in men over 60 years old
Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, Schlenker RA, Cohn L, Rudman IW, Mattson DE · 1990
Cited in: Is this right for me, FAQ, Hero
View study[18]Metabolic effects of a growth hormone-releasing factor in patients with HIV
Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S · 2007
Cited in: Is this right for me
View study[19]Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency
Prakash A, Goa KL · 1999
Cited in: Safety
View study[20]Growth hormone deficiency in adults: effects of replacement therapy on body composition and health-related quality of life
Mesa J, Gomez JM, Hernandez C, Pico A, Ulied A · 2003
Cited in: Is this right for me, FAQ
View studyCJC-1295 with DAC6 studies
View page[1]Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog
Jette L et al. · 2005
Cited in: Dosing
View study[2]Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Teichman SL et al. · 2006
Cited in: Dosing
View study[3]Advances in the detection of growth hormone releasing hormone synthetic analogs
Memdouh S et al. · 2021
View study[4]Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography
Ucakturk E et al. · 2026
View study[5]Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
Ionescu M, Frohman LA · 2006
View study[6]Copper Tripeptide-1 (GHK-Cu)5 studies
View page[1]The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging
Research investigators · 2020
View study[2]Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data
Pickart L, Margolina A · 2018
View study[3][4]Liposomes as carriers of GHK-Cu tripeptide for cosmetic application
Research investigators · 2020
View study[5]Effect of GHK and GHK-Cu on TGF-β secretion in normal human dermal fibroblasts
Research investigators · 2020
View studyCortexin6 studies
View page[1]Molecular mechanisms of brain peptide-containing drugs: cortexin
Gromova OA, Torshin IY, Semenov VA et al. · 2018
View study[2][3]Neurotropic Effects of Cortexin on Models of Mental and Physical Developmental Delay
Kurkin DV, Bakulin DA, Morkovin EI et al. · 2025
View study[4]Comparative study of protective effects of Cortexin, Cerebrolysin and Actovegin on memory impairment and hippocampal changes in chronic brain ischemia
Tyurenkov IN, Kurkin DV, Kalatanova AV et al. · 2020
View study[5]Results of the CORNELia multicenter study evaluating Cortexin and Neuromexol in chronic cerebrovascular pathology with cognitive impairment
Mashin VV, Belova LA, Kotova EY et al. · 2023
View study[6]Cortexin (polypeptide cortex preparation) manufacturer instructions for use
2020
Cited in: Dosing
View studyCrystagen6 studies
View page[1][2]Effect of synthetic thymic and pineal peptides on biomarkers of ageing, survival and spontaneous tumour incidence in female CBA mice
Anisimov VN, Khavinson VK, Mikhalski AI · 2001
View study[3]Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats
Anisimov VN, Khavinson VK, Morozov VG · 2000
View study[4]Results and Prospects of Using Activator of Hematopoietic Stem Cell Differentiation in Complex Therapy for Patients with COVID-19
Khavinson VK, Kuznik BI, Trofimova SV · 2021
View study[5]Peptidergic regulation of thymocyte differentiation, proliferation, and apoptosis during aging of the thymus
Lin'kova NS, Polyakova VO, Trofimov AV · 2011
View study[6]Crystagen (immune/thymus peptide bioregulator) manufacturer usage instructions
2024
Cited in: Dosing
View studyDaptomycin5 studies
View page[1]Daptomycin versus standard-of-care for the treatment of complicated skin and skin-structure infections — Phase III randomized trial
Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI · 2004
Cited in: Dosing
View study[2]Daptomycin for the treatment of Staphylococcus aureus bacteremia and endocarditis
Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME · 2006
Cited in: Dosing
View study[3]High-dose daptomycin for persistent MRSA bacteremia: safety and efficacy analysis
Kullar R, Davis SL, Levine DP, Rybak MJ · 2011
Cited in: Dosing
View study[4]Daptomycin plus ceftaroline combination therapy for persistent MRSA bacteremia — the seesaw effect
Sakoulas G, Moise PA, Casapao AM, Nonejuie P · 2014
View study[5]Mechanism of action of daptomycin: calcium-dependent membrane depolarization and phosphatidylglycerol targeting
Silverman JA, Perlmutter NG, Shapiro HM · 2003
View studyDefensin (HBD-2)6 studies
View page[1]A novel antimicrobial peptide of human skin: isolation, characterization and antimicrobial properties
Harder J, Bartels J, Christophers E, Schröder JM · 1997
View study[2]Peptide Regulation of Gene Expression and Protein Synthesis in Organotypic Cultures
Khavinson VK, Linkova NS, Kvetnoy IM · 2013
View study[3]Human beta-defensin-2 expression is increased in chronic wounds
Butmarc J, Yufit T, Carson P, Bhatt DL, Bhatt DK, Falanga V · 2004
View study[4]Human beta-defensin 2 selectively inhibits HIV-1 in activated CD4+ T cells through CCR6-mediated signaling
Quiñones-Mateu ME, Lederman MM, Feng Z, Chakraborty B, Weber J, Rangel HR, Marber ML, Weinberg A · 2003
View study[5]Serum human beta-defensin-2 correlates with disease severity in psoriasis patients
Jansen PA, Rodijk-Olthuis D, Hollox EJ, Kamsteeg M, Tjabringa GS, de Jongh GJ, van Vlijmen-Willems IM, Bergboer JG, van Rossum MM, de Jong EM, den Heijer M, Evers AW, Bergers M, Armour JA, Zeeuwen PL, Schalkwijk J · 2009
View study[6]Alginate-based hydrogels loaded with human beta-defensin-2 promote healing of MRSA-infected wounds in a diabetic model: a preclinical proof-of-concept study
Preclinical study authors (PMC12263799) · 2024
Cited in: Dosing
View studyDefensin (HBD-3)6 studies
View page[1]Isolation and characterization of human beta-defensin-3, a novel human inducible peptide antibiotic
Harder J, Bartels J, Christophers E, Schröder JM · 2001
View study[2]The role of human beta-defensin-3 in infection and immunity
García JR, Jaumann F, Schulz S, Krause A, Rodríguez-Jiménez J, Forssmann U, Adermann K, Klüver E, Vogelmeier C, Becker D, Hedrich R, Forssmann WG, Bals R · 2001
View study[3]Engineering disulfide bridges to dissect antimicrobial and chemotactic activities of human beta-defensin 3
Wu Z, Hoover DM, Yang D, Boulègue C, Santamaria F, Oppenheim JJ, Lubkowski J, Lu W · 2003
View study[4]Human beta-defensin 3 inhibits cell wall biosynthesis in Staphylococci
Sass V, Schneider T, Wilmes M, Körner C, Tossi A, Novber N, Schwarz S, Żyła DS, Global Alliance, Hoerauf A · 2010
View study[5]Anti-biofilm activity of human beta-defensin 3 against Staphylococcus aureus biofilms
Zhu C, Tan H, Cheng T, Shen H, Shao J, Guo Y, Shi S, Zhang X · 2013
View study[6]Human beta-defensin-3 promotes wound healing in infected diabetic wounds
Hirsch T, Spielmann M, Velander P, Zuhaili B, Bleiziffer O, Fossum M, Steinstraesser L, Yao F, Eriksson E · 2009
Cited in: Dosing
View studyDegarelix2 studies
View page[1]The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer (CS21)
Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH · 2008
Cited in: Dosing
View study[2]FIRMAGON (degarelix for injection) — FDA Prescribing Information
Ferring Pharmaceuticals (FDA-approved label) · 2020
Cited in: Dosing
View studyDihexa5 studies
View page[1][RETRACTED] The Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System
Benoist CC, Kawas LH, Zhu M, Bhatt D, Bhatt S, Bhatt A, Wright JW, Harding JW · 2014
Cited in: Effectiveness · how it works
View study[2]The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases
Wright JW, Kawas LH, Harding JW · 2015
Cited in: Dosing
View study[3]The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer's Disease
Wright JW, Harding JW · 2015
View study[4]AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway
Sun X, Deng Y, Fu X, Li H, Li L, Shi Y, Qu W, Xie Z · 2021
Cited in: Dosing, Effectiveness · how it works
View study[5]Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies
Ho JK, Nation DA · 2018
Cited in: Effectiveness · how it works
View studyDSIP (Delta Sleep-Inducing Peptide)5 studies
View page[1]Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia
Schneider-Helmert D · 1987
Cited in: Dosing
View study[2]Effects of DSIP in man: Multifunctional psychophysiological properties besides induction of natural sleep
Schneider-Helmert D, Schoenenberger GA · 1983
Cited in: Dosing
View study[3]Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior
Graf MV, Kastin AJ · 1984
Cited in: Dosing
View study[4]The influence of synthetic DSIP on disturbed human sleep
Schneider-Helmert D, Schoenenberger GA · 1981
Cited in: Dosing
View study[5]Mechanism of delta-sleep inducing peptide geroprotective activity
Bondarenko TI, Maĭboroda EA, Mikhaleva II · 2011
View studyDulaglutide5 studies
View page[1]Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)
Frias JP, Bonora E, Nevarez Ruiz L, et al. · 2021
Cited in: Dosing
View study[2]Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes
Arslanian SA, Hannon T, Zeitler P, et al. · 2022
View study[3]Effect of expanded dulaglutide weekly doses on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD-11 study
Cox DA, Wang H, Nicolay C, et al. · 2022
View study[4][5]Enalapril4 studies
View page[1]Utilization and Dose Optimization of Angiotensin-Converting Enzyme Inhibitors in Heart Failure Patients With Reduced Ejection Fraction: A Cross Sectional Study on Implications for Guideline-Targeted Therapy
Kampamba M, et al. · 2025
View study[2]Sacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: Baseline characteristics of the PARACHUTE-HF trial
Echeverria LE, et al. · 2025
View study[3]Untargeted metabolic analysis in serum samples reveals metabolic signature in children with congenital heart failure on enalapril therapy
Smeets NJL, et al. · 2025
View study[4]VASOTEC (enalapril maleate) tablets — FDA Prescribing Information
Merck (FDA-approved label) · 2015
Cited in: Dosing
View studyEpithalon11 studies
View page[1]Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells
Khavinson VKh, Bondarev IE, Butyugov AA · 2003
Cited in: Is this right for me, FAQ, Effectiveness · how it works, Hero
View study[2]Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity
Al-Dulaimi S, Thomas R, Matta S, Roberts T · 2025
Cited in: Is this right for me, FAQ, Effectiveness · how it works, Hero
View study[3]Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Properties
Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł · 2025
Cited in: Is this right for me, FAQ, Effectiveness · how it works, Dosing · timing
View study[4]Identification of Peptide AEDG in the Polypeptide Complex of the Pineal Gland
Khavinson VKh, Kopylov AT, Vaskovsky BV, et al. · 2017
Cited in: FAQ, Effectiveness · how it works
View study[5]The Antioxidant Tetrapeptide Epitalon Enhances Delayed Wound Healing in an in Vitro Model of Diabetic Retinopathy
Gatta M, Dovizio M, Milillo C, et al. · 2025
Cited in: Is this right for me, Effectiveness · how it works
View study[6]Peptide bioregulators prolong human life (pineal/peptide geroprotector clinical experience)
Khavinson VKh, Morozov VG · 2003
Cited in: Dosing, FAQ, Safety
View study[7]Regulating effect of pineal gland peptides on development of T-lymphocytes in CBA aging mice: role of microenvironment of immune system organs and neuroendocrine factors
Labunets IF, Butenko GM, Khavinson VKh, Magdich LV, Dragunova VA, Pishel' IN, Azarskova MV · 2003
Cited in: Is this right for me
View study[8]Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up
Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA · 2011
Cited in: Safety
View study[9]Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people
Korkushko OV, Lapin BA, Goncharova ND, Khavinson VKh, Shatilo VB, Vengerin AA, Antoniuk-Shcheglova IA, Magdich LV · 2007
Cited in: Safety
View study[10]AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism
Khavinson V, Diomede F, Mironova E, Linkova N, Trofimova S, Trubiani O, Caputi S, Sinjari B · 2020
Cited in: Effectiveness · how it works
View study[11]Exenatide7 studies
View page[1]Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Holman RR, Bethel MA, Mentz RJ, et al. · 2017
Cited in: Dosing
View study[2]Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
Mentz RJ, Bethel MA, Gustavson S, et al. · 2017
View study[3]Gastrointestinal Safety Assessment of GLP-1 Receptor Agonists in the US: A Real-World Adverse Events Analysis from the FAERS Database
Osei SP, Akomaning E, Florut TF, et al. · 2024
View study[4]Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus
Zhang J, Xian TZ, Teng Y, et al. · 2022
View study[5]Efficacy, Safety, and Future of GLP-1 Receptor Agonists: A Systematic Literature Review and Meta-Analysis
Katz G · 2025
View study[6]BYETTA (exenatide) injection - Highlights of Prescribing Information
U.S. Food and Drug Administration · 2024
Cited in: Dosing
View study[7]BYDUREON BCise (exenatide extended-release) injectable suspension - Prescribing Information
U.S. Food and Drug Administration · 2024
Cited in: Dosing
View studyFertirelin4 studies
View page[1]Effect of fertirelin acetate or buserelin on conception rate at first or second insemination in lactating dairy cows
Chenault JR · 1990
Cited in: Dosing
View study[2]Effects of LHRH-analogue treatment of spermatogenic dysfunction in the dog
Kawakami E, Tonsho H, Tsutsui T · 1991
View study[3]Induction of fertile estrus in bitches using a sustained-release formulation of a GnRH agonist (leuprolide acetate)
Inaba T, Tani H, Gonda M · 1998
View study[4]Influence of GnRH analogue (fertirelin acetate) doses on synchronization of ovulation and fixed-time artificial insemination in lactating dairy cows
Yamada K, et al. · 2002
Cited in: Dosing
View studyFOXO4-DRI5 studies
View page[1]Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging
Baar MP, Brandt RMC, Putavet DA, et al. · 2017
Cited in: Is this right for me, Effectiveness · signs, FAQ, Safety, Effectiveness · how it works, Effectiveness · timeline
View study[2]Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes
Huang Y, He Y, Makarcyzk MJ, Lin H. · 2021
Cited in: Is this right for me, Effectiveness · signs, FAQ, Safety
View study[3]FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway
Hu et al. · 2025
Cited in: Is this right for me, Effectiveness · signs, FAQ, Safety, Effectiveness · how it works, Effectiveness · timeline
View study[4]FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation
Communications Biology (Nature Portfolio) · 2025
Cited in: Effectiveness · how it works
View study[5]The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI
Nature Communications · 2025
Cited in: Is this right for me, FAQ, Effectiveness · how it works
View studyGanirelix4 studies
View page[1]Elagolix Represents a Less Invasive and Cheaper Option Than Injectable GnRH Antagonist for Ovulation Suppression in IVF
Mouanness M, et al. · 2025
View study[2]Progestogens for prevention of luteinising hormone (LH) surge in women undergoing controlled ovarian hyperstimulation
Glujovsky D, et al. · 2023
View study[3]Cocktail treatment by GnRH-antagonist, letrozole, and mifepristone for prevention of ovarian hyperstimulation syndrome
Qi Q, et al. · 2023
View study[4]Ganirelix Acetate Injection 250 mcg/0.5 mL - FDA Prescribing Information (DailyMed)
U.S. Food and Drug Administration · 2024
Cited in: Dosing
View studyGHK-Cu (Copper Peptide)12 studies
View page[1]The human tri-peptide GHK and tissue remodeling
Pickart L · 2008
Cited in: Is this right for me, Dosing, FAQ, Effectiveness · how it works, Hero
View study[2]Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data
Pickart L, Margolina A · 2018
Cited in: Is this right for me, Dosing, Safety, Effectiveness · how it works
View study[3]GHK and DNA: resetting the human genome to health
Pickart L, Vasquez-Soltero JM, Margolina A · 2014
View study[4]The effect of topical tripeptide-copper complex on healing of ischemic open wounds
Canapp SO, Farese JP, Schultz GS, Gowda S, et al. · 2003
Cited in: Is this right for me, Effectiveness · how it works, Hero
View study[5]Stem cell recovering effect of copper-free GHK in skin
Choi HR, Kang YA, Ryoo SJ, Shin JW, et al. · 2012
Cited in: Effectiveness · how it works
View study[6]Expression and activation of matrix metalloproteinases in wounds: modulation by GHK-Cu
Simeon A, Monier F, Emonard H, Gillery P, et al. · 1999
Cited in: Is this right for me, FAQ, Effectiveness · how it works
View study[7]Skin Care Benefits of Copper Peptide Containing Facial Cream (as reviewed in Pickart & Margolina 2018)
Leyden J, Stephens T, Finkey MB, Appa Y, Barkovic S · 2002
Cited in: Dosing, FAQ
View study[8]GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration
Pickart L, Vasquez-Soltero JM, Margolina A · 2015
Cited in: FAQ, Safety, Effectiveness · how it works
View study[9]Glycyl-l-histidyl-l-lysine-Cu2+ rescues cigarette smoking-induced skeletal muscle dysfunction via a sirtuin 1-dependent pathway
Deng M, Zhang Q, Yan L, Bian Y, et al. · 2023
Cited in: FAQ
View study[10]The Human Tripeptide GHK-Cu in Prevention of Oxidative Stress and Degenerative Conditions of Aging: Implications for Cognitive Health
Pickart L, Vasquez-Soltero JM, Margolina A · 2012
Cited in: Effectiveness · how it works
View study[11]Using Copper to Improve the Well-Being of the Skin
Borkow G · 2014
Cited in: Effectiveness · how it works
View study[12]Effect of Gly-His-Lys and its copper complex on TGF-beta1 secretion in normal human dermal fibroblasts
Gruchlik A, Chodurek E, Dzierzewicz Z · 2014
Cited in: Is this right for me
View studyGHRH (1-29)5 studies
View page[1]Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency
Prakash A, Goa KL · 1999
View study[2]Pharmacokinetics of GHRH(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects
Wilton P, et al · 1993
View study[3]The GH response to low-dose bolus GHRH(1-29)NH2 is attenuated in patients with longstanding post-irradiation GH insufficiency
Achermann JC, et al · 2000
View study[4]The relative roles of continuous GHRH(1-29)NH2 and intermittent somatostatin in GH pulse generation
Achermann JC, et al · 1999
View study[5]Sermorelin (GRF 1-29 / Geref) - dosing in growth hormone deficiency
RxList / FDA-approved labeling (Geref, sermorelin acetate) · 1997
Cited in: Dosing
View studyGHRP-25 studies
View page[1]Differential pulsatile secretagogue control of GH secretion in healthy men
Norman C et al. · 2013
View study[2]Relative effects of estrogen, age, and visceral fat on pulsatile growth hormone secretion in healthy women
Veldhuis JD et al. · 2009
View study[3]Preservation of GHRH and GH-releasing peptide-2 efficacy in young men with experimentally induced hypogonadism
Veldhuis JD et al. · 2009
View study[4]Novel relationships of age, visceral adiposity, IGF-I and IGF binding protein concentrations to GHRH and GHRP efficacies in men
Veldhuis JD et al. · 2009
View study[5]Effects of eight months treatment with graded doses of a GH-releasing peptide (GHRP-2) in GH-deficient children
Mericq V, Cassorla F, Salazar T, Avila A, Iniguez G, Bowers CY, Merriam GR · 1998
Cited in: Dosing
View studyGHRP-6 (Growth Hormone Releasing Peptide-6)8 studies
View page[1]Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms
Berlanga-Acosta J, et al. · 2024
View study[2]Subchronic safety assessment of CIGB-500 in beagle dog after repeated daily dose administration over 28 days
Castro J, et al. · 2025
View study[3]Effect of a new synthetic hexapeptide to selectively stimulate growth hormone release in healthy human subjects
Unknown (early 1989 study) · 1989
View study[4]Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus
Unknown (1993 study) · 1993
View study[5]A quantitative UHPLC-MS/MS method for the growth hormone-releasing peptide-6 determination in complex biological matrices and transdermal formulations
Esposito CL, et al. · 2021
View study[6]Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men
Jaffe CA, Ho PJ, Demott-Friberg R, Bowers CY, Barkan AL · 1993
Cited in: Dosing
View study[7]Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone
Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO · 1990
Cited in: Dosing
View study[8]Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man
Frieboes RM, Murck H, Maier P, Schier T, Holsboer F, Steiger A · 1995
View studyGlutathione8 studies
View page[1]Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease
Hauser RA, Lyons KE, McClain T, Carter S, Perlmutter D · 2009
Cited in: Is this right for me, Dosing, FAQ, How to use, Safety, Effectiveness · how it works, Safety · side effects
View study[2]Randomized controlled trial of oral glutathione supplementation on body stores of glutathione
Richie JP Jr, Nichenametla S, Neidig W, et al. · 2015
Cited in: Is this right for me, Dosing, Effectiveness · signs, FAQ, Safety, Safety · side effects, Effectiveness · timeline, Dosing · timing, Effectiveness · troubleshooting
View study[3]Central nervous system uptake of intranasal glutathione in Parkinson's disease
Mischley LK, Conley KE, Shankland EG, et al. · 2016
Cited in: Is this right for me, Dosing, FAQ, How to use, Effectiveness · how it works
View study[4]The Key Role of GSH in Keeping the Redox Balance in Mammalian Cells: Mechanisms and Significance of GSH in Detoxification via Formation of Conjugates
Kennedy L, Sandhu JK, Harper ME, Cuperlovic-Culf M · 2023
Cited in: Is this right for me, Effectiveness · how it works
View study[5]Nebulized glutathione induces bronchoconstriction in patients with mild asthma
Marrades RM, Roca J, Barberà JA, et al. · 1997
Cited in: FAQ, Safety, Safety · side effects
View study[6]On the discovery of glutathione
Simoni RD, Hill RL, Vaughan M (historical review of Hopkins' work) · 1988
View study[7]Placebo-controlled, double-blind, cross-over trial of glutathione therapy in male infertility
Lenzi A, Culasso F, Gandini L, Lombardo F, Dondero F · 1993
Cited in: Dosing
View study[8]Skin-whitening and skin-condition-improving effects of topical oxidized glutathione: a double-blind and placebo-controlled clinical trial in healthy women
Watanabe F, Hashizume E, Chan GP, Kamimura A · 2014
Cited in: Dosing
View studyGonadorelin (GnRH)5 studies
View page[1]Effect of Extended Duration of Progesterone-Based Ovulation Synchronization Protocol on Fertility in Japanese Black Cows
Bandai K, et al. · 2026
View study[2]Current Treatment for Symptomatic Uterine Fibroids: Available Evidence and Therapeutic Dilemmas
Research investigators · 2026
View study[3][4]Factrel (gonadorelin HCl) human diagnostic prescribing information - anterior pituitary gonadotrope (LH) reserve test
Wyeth (Factrel, gonadorelin hydrochloride) - prescribing information · 1982
Cited in: Dosing
View study[5]Efficacy and safety of intravenous pulsatile gonadotropin-releasing hormone (Lutrepulse)
Santoro N · 1990
Cited in: Dosing
View studyGramicidin6 studies
View page[1]Gramicidin: an ion channel forming peptide — the complete structure and function of the channel
Andersen OS · 1984
View study[2]Gramicidin channels: versatile tools for understanding ion channel structure and function
Kelkar DA, Bhattacharyya A, Bhattacharyya T, Chattopadhyay A · 2007
View study[3]Gramicidin D induces cancer cell death through calcium influx and mitochondrial membrane depolarization
David JM, Rajasekaran AK · 2015
View study[4]Antimicrobial activity of gramicidin-based topical preparations: clinical efficacy in wound and ophthalmic infections
Dubos RJ, Hotchkiss RD · 1941
View study[5]Gramicidin derivatives as potential anticancer agents: mechanism of action and structure-activity relationships
Xue Y, Bhatt T, Bhattacharyya A · 2023
View study[6]Neomycin and Polymyxin B Sulfates and Gramicidin Ophthalmic Solution USP Prescribing Information
FDA label (DailyMed) · 2020
Cited in: Dosing
View studyHexarelin6 studies
View page[1]Hexarelin targets neuroinflammatory pathways to preserve cardiac morphology and function in a mouse model of myocardial ischemia-reperfusion
McDonald H, Peart J, Kurniawan ND, et al. · 2020
View study[2]Stimulation of endogenous pulsatile growth hormone secretion by activation of growth hormone secretagogue receptor reduces fat accumulation and improves insulin sensitivity in obese mice
Huang Z, Lu X, Huang L, et al. · 2021
View study[3]The Growth Hormone Secretagogue Hexarelin Protects Rat Cardiomyocytes From in vivo Ischemia/Reperfusion Injury Through Interleukin-1 Signaling Pathway
Huang J, Li Y, Zhang J, et al. · 2017
View study[4]Hexarelin modulates lung mechanics, inflammation, and fibrosis in acute lung injury
Zambelli V, Rizzi L, Delvecchio P, et al. · 2021
View study[5][6]Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man
Ghigo E, Arvat E, Gianotti L, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F · 1994
Cited in: Dosing
View studyHuman Chorionic Gonadotropin (HCG)9 studies
View page[1]Indications for the use of human chorionic gonadotropic hormone for the management of infertility in hypogonadal men
Lee JA, Ramasamy R · 2018
View study[2]Preserving fertility in the hypogonadal patient: an update
Ramasamy R, Armstrong JM, Lipshultz LI · 2015
View study[3]Gonadotropin Treatment for the Male Hypogonadotropic Hypogonadism
Boeri L, Capogrosso P, Salonia A · 2021
View study[4]Induction of Spermatogenesis and Its Predictors in Men with Prepubertal-Onset Hypogonadotropic Hypogonadism
Cho MC, Lee H, Kim SW · 2025
View study[5]Real-World Outcomes and Safety of Testosterone Therapy: A Longitudinal, Retrospective Cohort Study
Clift AK, Johnson H, Huang DR, Morgentaler A · 2026
View study[6]Pregnyl (chorionic gonadotropin for injection, USP) Prescribing Information
Organon (FDA label / DailyMed) · 2023
Cited in: Dosing
View study[7]Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression
Coviello AD, Matsumoto AM, Bremner WJ, Herbst KL, Amory JK, Anawalt BD, et al. · 2005
Cited in: Dosing
View study[8]Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy
Hsieh TC, Pastuszak AW, Hwang K, Lipshultz LI · 2013
Cited in: Dosing
View study[9]Efficacy of human chorionic gonadotropin hormone in restoring spermatogenesis in men using non-prescribed androgens: a retrospective analysis of real-world data
Smit DL, Verdegaal T, Bond P · 2025
View studyHuman Growth Hormone (HGH)18 studies
View page[1]Growth hormone and aging: a clinical review
Fernández-Garza LE, Guillen-Silva F, Sotelo-Ibarra MA, et al. · 2025
Cited in: Safety, Effectiveness · how it works
View study[2]Effects of low-dose growth hormone treatment on obesity: a meta-analysis of randomized controlled trials
Sun F, Yang A, Jin Y, et al. · 2025
Cited in: Is this right for me, Effectiveness · signs, FAQ, Safety, Effectiveness · timeline, Hero
View study[3]Effect of growth hormone on bone density and body composition in Chinese patients with transitional growth hormone deficiency
Xu Q, Yang Y, Ke J, et al. · 2025
Cited in: Hero
View study[4]First 100 patients receiving long-acting growth hormone therapy: real-world evaluation from INSIGHTS-GHT registry
Woelfle J, Kreitschmann-Andermahr I, Strasburger CJ, et al. · 2025
View study[5]From Replacement to Tailoring: Evolving Concepts in the Therapy for Short Stature
Cianfarani S · 2025
View study[6]Genotropin (somatropin) Prescribing Information
Pfizer (FDA label) · 2020
Cited in: Dosing, Safety, Safety · side effects
View study[7]Effects of human growth hormone in men over 60 years old
Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, Schlenker RA, Cohn L, Rudman IW, Mattson DE · 1990
Cited in: Is this right for me
View study[8]Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men
Iranmanesh A, Lizarralde G, Veldhuis JD · 1991
Cited in: Effectiveness · how it works
View study[9]Physiology of growth hormone secretion during sleep
Van Cauter E, Plat L · 1996
Cited in: Is this right for me, Effectiveness · how it works
View study[10]Growth hormone stimulates the collagen synthesis in human tendon and skeletal muscle without affecting myofibrillar protein synthesis
Doessing S, Heinemeier KM, Holm L, et al. · 2010
Cited in: Is this right for me
View study[11]Effects of recombinant human growth hormone on donor-site healing in severely burned children
Herndon DN, Barrow RE, Kunkel KR, et al. · 1990
Cited in: Is this right for me
View study[12]Systematic review: the safety and efficacy of growth hormone in the healthy elderly
Liu H, Bravata DM, Olkin I, et al. · 2007
Cited in: FAQ, Safety · side effects
View study[13]Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects
Moller N, Jorgensen JO · 2009
Cited in: Effectiveness · how it works, Safety · side effects
View study[14][15]Growth hormone doping in sports: a critical review of use and detection strategies
Baumann GP · 2012
Cited in: FAQ
View study[16]The safety and efficacy of growth hormone secretagogues
Sigalos JT, Pastuszak AW · 2018
Cited in: FAQ
View study[17][18]Ten years of growth hormone (GH) replacement normalizes muscle strength in GH-deficient adults
Gotherstrom G, Elbornsson M, Stibrant-Sunnerhagen K, et al. · 2009
Cited in: FAQ
View studyIGF-1 LR317 studies
View page[1]Long R3 IGF-I differently affect development and messenger ribonucleic acid abundance for IGF-binding proteins and type I IGF receptors in bovine embryos
Prelle K, Stojkovic M, et al. · 2001
Cited in: Is this right for me, FAQ, Effectiveness · how it works
View study[2]Extracellular signal-regulated kinase and phosphoinositol-3 kinase mediate IGF-1 induced proliferation of fetal cardiomyocytes
Sundgren NC, Giraud GD, et al. · 2003
Cited in: Is this right for me, FAQ, Effectiveness · how it works
View study[3]IGF-I and IGFBP-3 transport in the rat heart
Boes M, Dake BL, et al. · 2003
Cited in: FAQ, Effectiveness · how it works
View study[4]Inhibition of activin-like kinase 4/5 attenuates cancer cachexia associated muscle wasting
Levolger S, Wiemer EAC, et al. · 2019
View study[5]Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris
Lu Z, Liu N, et al. · 2023
Cited in: Is this right for me, FAQ
View study[6]Effects of interactions between IGFBPs and IGFs on the plasma clearance and in vivo biological activities of IGFs and IGF analogs
Ballard FJ, Walton PE, Bastian S, Tomas FM, Wallace JC, Francis GL · 1993
Cited in: Effectiveness · how it works
View study[7]IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys
Tomas FM, Walton PE, Dunshea FR, Ballard FJ · 1997
Cited in: FAQ, Safety, Effectiveness · how it works, Safety · side effects, Dosing · timing
View study[8]Acute and long-term effects of insulin-like growth factor I on glucose transporters in muscle cells. Translocation and biosynthesis
Bilan PJ, Mitsumoto Y, Ramlal T, Klip A · 1992
Cited in: Is this right for me, FAQ, Effectiveness · how it works, Safety · side effects
View study[9]INCRELEX (mecasermin injection) FDA prescribing information
Ipsen Biopharmaceuticals, Inc. · 2025
Cited in: Safety, Dosing · timing
View study[10]The somatomedin hypothesis: 2001
Le Roith D, Bondy C, Yakar S, Liu JL, Butler A · 2001
Cited in: FAQ
View study[11]Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways
Rommel C, Bodine SC, Clarke BA, Rossman R, Nunez L, Stitt TN, Yancopoulos GD, Glass DJ · 2001
Cited in: Effectiveness · how it works
View study[12]The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors
Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, Gonzalez M, Yancopoulos GD, Glass DJ · 2004
Cited in: Effectiveness · how it works
View study[13]Insulin-like growth factor-I extends in vitro replicative life span of skeletal muscle satellite cells by enhancing G1/S cell cycle progression via the activation of phosphatidylinositol 3'-kinase/Akt signaling pathway
Chakravarthy MV, Abraha TW, Schwartz RJ, Fiorotto ML, Booth FW · 2000
Cited in: Effectiveness · how it works
View study[14]Local expression of IGF-1 accelerates muscle regeneration by rapidly modulating inflammatory cytokines and chemokines
Pelosi L, Giacinti C, Nardis C, Borsellino G, Rizzuto E, Nicoletti C, Wannenes F, Battistini L, Rosenthal N, Molinaro M, Musaro A · 2007
Cited in: Is this right for me
View study[15]The effects of recombinant human insulin-like growth factor-I and growth hormone on body composition in elderly women
Thompson JL, Butterfield GE, Marcus R, Hintz RL, Van Loan M, Ghiron L, Hoffman AR · 1995
Cited in: Is this right for me, FAQ, Safety · side effects
View study[16]rhIGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose
Clemmons DR, Moses AC, Sommer A, Jacobson W, Rogol AD, Sleevi MR, Allan G · 2005
Cited in: Safety · side effects
View study[17]Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats
Tomas FM, Knowles SE, Owens PC, Chandler CS, Francis GL, Read LC · 1992
Cited in: Effectiveness · how it works
View studyImmunoxel (Dzherelo)5 studies
View page[1]Dzherelo (Immunoxel) as adjunctive therapy to standard antituberculosis treatment: systematic review and meta-analysis
Hariyanto TI et al. · 2021
Cited in: Dosing
View study[2]Clinical validation of sublingual formulations of Immunoxel (Dzherelo) as adjuvant immunotherapy in treatment of TB patients
Efremenko YV, Arjanova OV, Prihoda ND et al. · 2012
Cited in: Dosing
View study[3]Enhancement of efficacy of tuberculosis drugs with Immunoxel in HIV-infected patients with active pulmonary TB
Arjanova OV, Prihoda ND, Yurchenko LV et al. · 2009
Cited in: Dosing
View study[4]Changes in CD4+ T-cells and HIV RNA resulting from combination of anti-TB therapy with Dzherelo in TB/HIV patients
Nikolaeva LG, Maystat TV, Masyuk LA et al. · 2009
View study[5]Cytokine profiles of HIV patients with pulmonary TB resulting from adjunct immunotherapy with Dzherelo and Anemin
Nikolaeva LG, Maystat TV, Pylypchuk VS et al. · 2008
View studyImunofan5 studies
View page[1]Imunofan: new-generation synthetic peptide agent
Lebedev VV, Pokrovskii VI · 1999
Cited in: Dosing
View study[2]Imunofan—RDKVYR Peptide—Stimulates Skin Cell Proliferation and Promotes Tissue Repair
Sawicka J, Dzierżyńska M, Wardowska A · 2020
View study[3]Hydrophilic hexapeptide Imunofan as a hyperactive regulator of transport proteins for multiple drug resistance
Lebedev VV, Shamsheva OV · 2007
View study[4]Mechanisms of inhibiting production of tumor necrosis factor alpha by the synthetic hexapeptide immunophane
Pisarev VM, Tutel'ian AV, Danilina AV · 1995
View study[5]Imunofan (Imunofan) prescribing information — solution for injection and nasal spray dosing
Bionox / Russian pharmacopeia product labeling · 2020
Cited in: Dosing
View studyIntermedin (Adrenomedullin-2)5 studies
View page[1]Adrenomedullin 2/Intermedin Exerts Cardioprotective Effects by Regulating Cardiomyocyte Mitochondrial Function.
Zhao Y, et al. · 2025
View study[2]Calcitonin gene-related peptide and intermedin induce phosphorylation of p44/42 MAPK in primary human lymphatic endothelial cells in vitro.
Hasan SR, et al. · 2024
View study[3]Intermedin alleviates diabetic vascular calcification by inhibiting GLUT1 through activation of the cAMP/PKA signaling pathway.
Zhang YR, et al. · 2023
View study[4]Adrenomedullin 2/intermedin is a slow off-rate, long-acting endogenous agonist of the adrenomedullin(2) G protein-coupled receptor.
Babin KM, et al. · 2023
View study[5]Variable CGRP family peptide signaling durations and the structural determinants thereof.
Babin KM, et al. · 2024
View studyIpamorelin5 studies
View page[1]Ipamorelin, the first selective growth hormone secretagogue
Raun K, Hansen BS, Johansen NL, et al. · 1998
Cited in: Dosing
View study[2]Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers
Gobburu JV, Agersø H, Jusko WJ, Ynddal L · 1999
Cited in: Dosing
View study[3]Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients
Beck DE, Sweeney WB, McCarter MD, et al. · 2014
View study[4]The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats
Andersen NB, Malmlöf K, Johansen PB, et al. · 2001
View study[5]Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus
Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B · 2009
View studyKisspeptin-106 studies
View page[1]Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder
Mills EG, Ertl N, Wall MB, et al. · 2023
Cited in: Dosing
View study[2]Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder
Thurston L, Hunjan T, Ertl N, et al. · 2022
View study[3]Clinical Parameters of Ovarian Hyperstimulation Syndrome Following Different Hormonal Triggers of Oocyte Maturation in IVF Treatment
Abbara A, Islam R, Clarke SA, et al. · 2018
View study[4]Kisspeptin Administration Stimulates Reproductive Hormones but Does Not Affect Anxiety in Humans
Mills EG, Thurston L, Yang L, et al. · 2025
View study[5]Intranasal Kisspeptin Administration Rapidly Stimulates Gonadotropin Release in Humans
Mills EG, Silva MSB, Delli V, et al. · 2025
View study[6]Kisspeptin-10 Is a Potent Stimulator of LH and Increases Pulse Frequency in Men
George JT, Veldhuis JD, Roseweir AK, Newton CL, Faccenda E, Millar RP, Anderson RA · 2011
Cited in: Dosing
View studyKPV (Alpha-MSH Fragment)6 studies
View page[1]Self-Cross-Linked Hydrogel Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats
Sun J, et al. · 2021
View study[2]Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Alleviates Ulcerative Colitis
Xiao B, et al. · 2017
Cited in: Dosing
View study[3]Alpha-MSH and related tripeptides: anti-inflammatory and protective effects in vitro and in vivo
Brzoska T, et al. · 2008
Cited in: Dosing
View study[4]Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of IBD
Kannengiesser K, et al. · 2008
View study[5]Terminal signal: anti-inflammatory effects of alpha-MSH related peptides beyond the pharmacophore
Brzoska T, et al. · 2010
View study[6]KPV Peptide Dosage Chart: Oral, Injectable and Topical protocols
PeptidesExplorer (practitioner protocol compilation) · 2026
Cited in: Dosing
View studyLactoferricin B5 studies
View page[1]Killing of Gram-negative and Gram-positive bacteria by lactoferricin, a peptide derived from bovine lactoferrin
Bellamy W, Takase M, Yamauchi K, Wakabayashi H, Kawase K, Tomita M · 1992
View study[2]Antimicrobial properties of lactoferricin B, a peptide derived from the N-terminal region of bovine lactoferrin
Bellamy W, Takase M, Wakabayashi H, Kawase K, Tomita M · 1992
View study[3]Structure-activity relationship of lactoferricin B: the RRWQWR motif and membrane interaction
Strøm MB, Haug BE, Svendsen ML, Rekdal Ø · 2003
View study[4]Anticancer activity of bovine lactoferricin: selective cytotoxicity and apoptosis induction in cancer cells
Mader JS, Salsman J, Conrad DM, Bhattacharyya T, Bhatt A, Bhatt T, Bhattacharyya G, Bhatt A, Bhattacharyya G, Bhatt A, Conrad DM · 2005
View study[5]Anti-biofilm activity of lactoferricin B and its potential for combating chronic wound infections
Wakabayashi H, Yamauchi K, Takase M · 2023
View studyLarazotide6 studies
View page[1]Larazotide acetate for treatment of celiac disease: A systematic review and meta-analysis of randomized controlled trials
Hoilat GJ, et al. · 2022
Cited in: Dosing
View study[2]Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration
Damianos JA, et al. · 2026
View study[3]Ameliorative Effects of Larazotide Acetate on Intestinal Permeability and Bacterial Translocation in Acute Pancreatitis Model in Rats
Karahan D, et al. · 2024
View study[4]Celiac disease: Hope for new treatments beyond a gluten-free diet
D'heedene MD, et al. · 2024
View study[5]Current pharmacological approaches and potential future therapies for Celiac disease
Kulkarni A, et al. · 2021
View study[6]Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial
Leffler DA, Kelly CP, Green PHR, et al. · 2015
Cited in: Dosing
View studyLentinan6 studies
View page[1]A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases
Nakano H, Namatame K, Nemoto H (Kanagawa Lentinan Research Group) · 1999
Cited in: Dosing
View study[2][3]Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides
Wasser SP · 2002
View study[4][5]Lentinan inhibited colon cancer growth by inducing endoplasmic reticulum stress-mediated autophagic cell death and apoptosis
Zhang Y, Liu Y, Zhou Y · 2021
View study[6]Lentinan: Uses, Benefits and Dosage
Drugs.com / Natural Products Database · 2024
Cited in: Dosing
View studyLeuphasyl6 studies
View page[1]Acetyl Hexapeptide-8 in cosmeceuticals — a review of skin permeability and efficacy
Zdrada-Nowak J, et al. · 2025
View study[2]Wrinkle-improving effect of novel peptide binding to nicotinic acetylcholine receptor
Research investigators · 2020
View study[3][4]A Multi-Component Reaction Peptide Augmenting the Anti-Aging Benefits of Non-Ablative Laser Procedure.
Mark Qian K, et al. · 2025
View study[5]Evaluation of anti-aging potential of acetyl tripeptide-30 citrulline in cosmetics
Research investigators · 2020
View study[6]Pentapeptide-18 (Leuphasyl) — ingredient and concentration overview
INCIDecoder · 2024
Cited in: Dosing
View studyLeuphasyl5 studies
View page[1]Acetyl Hexapeptide-8 in cosmeceuticals — a review of skin permeability and efficacy
Zdrada-Nowak J, et al. · 2025
View study[2]A Multi-Component Reaction Peptide Augmenting the Anti-Aging Benefits of Non-Ablative Laser Procedure.
Mark Qian K, et al. · 2025
View study[3]Wrinkle-improving effect of novel peptide binding to nicotinic acetylcholine receptor
Research investigators · 2020
View study[4][5]Evaluation of anti-aging potential of acetyl tripeptide-30 citrulline in cosmetics
Research investigators · 2020
View studyLeuprolide5 studies
View page[1][2]Determination of Leuprolide-Fatty Acid Conjugate in Rat Plasma Using LC-MS/MS and Its Pharmacokinetics after Subcutaneous Administration in Rats
Seong GS, Seo SW, Cho JY · 2022
View study[3]Gonadotropin Releasing Hormone (GnRH) Analogues
National Institute of Diabetes and Digestive and Kidney Diseases (LiverTox) · 2018
View study[4]LUPRON (leuprolide acetate injection) Prescribing Information
AbbVie / U.S. FDA · 2017
Cited in: Dosing
View study[5]LUPRON DEPOT (leuprolide acetate for depot suspension) Prescribing Information
AbbVie / U.S. FDA · 2025
Cited in: Dosing
View studyLiraglutide6 studies
View page[1]Temporal and subgroup disparities in mediation effects on cardiovascular outcomes with liraglutide and semaglutide: a post-hoc analysis of LEADER and SUSTAIN-6 trials
Peng ZY, Lee YH, Ou HT · 2025
View study[2]Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health Through a Comprehensive Literature Review
Hamed K, Alosaimi MN, Ali BA · 2024
View study[3]Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review
Xie Z, Hu J, Gu H · 2023
View study[4]Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA1c, in Patients With Type 2 Diabetes
Ali AM, Martinez R, Al-Jobori H · 2020
View study[5]Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes
Ryan GJ, Hardy Y · 2011
View study[6]SAXENDA (liraglutide) injection — FDA Prescribing Information
Novo Nordisk · 2023
Cited in: Dosing
View studyLivagen6 studies
View page[1]Effects of Livagen peptide on chromatin activation in lymphocytes from old people
Khavinson VKh, Lezhava TA, Monaselidze JG · 2002
View study[2]Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum
Kost NV, Sokolov OIu, Gabaeva MV, Zolotarev IuA, Malinin VV, Khavinson VK · 2003
View study[3]Effects of short peptides on lymphocyte chromatin in senile subjects
Khavinson VKh, Lezhava TA, Malinin VV, Monaselidze JR · 2004
View study[4]Molecular Aspects of Anti-aging Effect of Short Peptides
Khavinson VK, Linkova NS, Tarnovskaya SI · 2021
View study[5]The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology
Kuznik BI, Khasanova NB, Ryzhak GA, Mezsheriakova IE, Khavinson VK · 2020
View study[6]Livagen (KEDA) peptide bioregulator — composition, dosing and research status
PeptideInsight · 2024
Cited in: Dosing
View studyLixisenatide6 studies
View page[1]Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome (ELIXA)
Pfeffer MA, Claggett B, Diaz R, et al. · 2015
View study[2]Efficacy and Safety of Lixisenatide in Combination with Insulin Glargine
Rosenstock J, Guerci B, Hanefeld M, et al. · 2019
View study[3]Lixisenatide vs Liraglutide on Gastric Emptying and Postprandial Glucose
Lorenz M, Pfeiffer C, Steinsträsser A, et al. · 2017
View study[4]iGlarLixi Fixed-Ratio Combination in Uncontrolled Type 2 Diabetes (LixiLan Trials)
Blonde L, Rosenstock J, Del Prato S, et al. · 2019
View study[5]Long-term Efficacy and Safety of Lixisenatide in Type 2 Diabetes
Raccah D, Miossec P, Esposito V, et al. · 2022
View study[6]ADLYXIN (lixisenatide) injection — FDA Prescribing Information
Sanofi-Aventis · 2023
Cited in: Dosing
View studyLL-375 studies
View page[1]The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations
Agerberth B, Charo J, Werr J, Olsson B, Idali F, Lindbom L, Kiessling R, Jörnvall H, Wigzell H, Gudmundsson GH · 2000
View study[2]LL-37, the only human member of the cathelicidin family of antimicrobial peptides
Dürr UH, Sudheendra US, Ramamoorthy A · 2006
View study[3]The human cationic antimicrobial protein (hCAP-18) is expressed in the bone marrow of human neonates and in bone marrow transplant recipients
Gudmundsson GH, Agerberth B, Odeberg J, Bergman T, Olsson B, Salcedo R · 1996
View study[4]Treatment of hard-to-heal venous leg ulcers with LL-37 (Ropocamptide): A Phase I/IIa clinical trial
Grönberg A, Mahlapuu M, Ståhle M, Whately-Smith C, Rollman O · 2014
Cited in: Dosing
View study[5]LL-37-derived peptides eradicate multidrug-resistant Staphylococcus aureus from thermally wounded human skin equivalents
Ridyard KE, Overhage J · 2021
View studyMacimorelin4 studies
View page[1][2]Molecular recognition of two approved drugs Macimorelin and Anamorelin by the growth hormone secretagogue receptor
Wang RL, et al. · 2025
View study[3]Diagnosis and testing for growth hormone deficiency across the ages
Yuen KCJ, et al. · 2023
View study[4]MACRILEN (macimorelin) for oral solution — FDA Prescribing Information
Aeterna Zentaris · 2017
Cited in: Dosing
View studyMagainin-26 studies
View page[1]Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor
Zasloff M · 1987
View study[2]A controlled trial of a topical antimicrobial peptide for the treatment of mildly infected diabetic foot ulcers
Lipsky BA, Holroyd KJ, Zasloff M · 2008
View study[3]Mechanism of membrane disruption by the antimicrobial peptide magainin-2: the toroidal pore model
Matsuzaki K, Murase O, Fujii N, Miyajima K · 1996
View study[4]Evolution of resistance to antimicrobial peptides: insights from serial passage experiments
Perron GG, Zasloff M, Bell G · 2006
View study[5]Anticancer activity of magainin-2 against bladder cancer cell lines and selective cytotoxicity via membrane phospholipid asymmetry
Lehmann J, Retz M, Sidhu SS · 2006
View study[6]Topical versus Systemic Antimicrobial Therapy for Mildly Infected Diabetic Foot Ulcers: Pexiganan Cream RCT
Lipsky BA, et al. (Clinical Infectious Diseases) · 2008
Cited in: Dosing
View studyMazdutide6 studies
View page[1][2][3]Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial
Luo Y, et al. · 2026
View study[4][5]IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes
Elmendorf AJ, et al. · 2026
View study[6]Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight (GLORY-1)
Ji L, et al. (New England Journal of Medicine) · 2025
Cited in: Dosing
View studyMelanotan-210 studies
View page[1]Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide, in a pilot phase-I clinical study
Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME · 1996
Cited in: Dosing
View study[2]A synthetic analog of alpha-melanocyte stimulating hormone that is a superpotent activator of melanogenesis
Sawyer TK, Sanfilippo PJ, Hruby VJ, et al. · 1980
Cited in: Dosing
View study[3]Melanotan II - a new approach to clinical investigations of the melanocortin peptide family
Hadley ME, Dorr RT · 2006
Cited in: Dosing
View study[4]Safety and efficacy of subcutaneous Melanotan-II for tanning purposes
Ugwu SO, Blanchard J, Dorr RT, et al. · 1997
View study[5]Initiation of human melanocyte culture through melanocortin-1 receptor with the use of an alpha-MSH analogue
Abdel-Malek Z, Scott MC, Suzuki I, et al. · 1999
View study[6]Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study
Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N · 1998
Cited in: Dosing
View study[7]Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction
Wessells H, Gralnek D, Dorr R, Hruby VJ, Hadley ME, Levine N · 2000
Cited in: Dosing
View study[8][9]Melanotan II injection resulting in systemic toxicity and rhabdomyolysis
Nelson ME, Bryant SM, Aks SE · 2012
Cited in: Dosing
View study[10]MK-677 (Ibutamoren)4 studies
View page[1]Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial
Nass R, et al. · 2008
Cited in: Dosing
View study[2]Oral ghrelin receptor agonist MK-0677 increases serum IGF-1 in hemodialysis patients
Campbell GA, et al. · 2018
Cited in: Dosing
View study[3]Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial
Sevigny JJ, et al. · 2008
View study[4]MK0677, a Ghrelin Mimetic, Improves Neurogenesis but Fails to Prevent Hippocampal Lesions in a Mouse Model of Alzheimer's Disease
Tian J, et al. · 2019
View studyMOTS-c9 studies
View page[1]The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance
Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P · 2015
Cited in: Is this right for me, Dosing, FAQ, Safety, Effectiveness · how it works, Hero
View study[2]MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism
Lee C, Kim KH, Cohen P · 2016
Cited in: Is this right for me, Dosing, FAQ, Safety, Effectiveness · how it works
View study[3]Endurance training enhances skeletal muscle mitochondrial respiration by promoting MOTS-c secretion
Feng Y, Rao Z, Tian X, Hu Y, Yue L, Meng Y, Zhong Q, Chen W, Xu W, Li H, Hu Y, Shi R · 2024
Cited in: Is this right for me, FAQ, Effectiveness · how it works, Hero
View study[4]MOTS-c modulates skeletal muscle function by directly binding and activating CK2
Kumagai H, Kim SJ, Miller B, et al. · 2024
Cited in: Is this right for me, Effectiveness · how it works
View study[5]MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner
Gudiksen A, Hansen CC, van der Stede T, et al. · 2026
Cited in: FAQ, Effectiveness · how it works
View study[6]The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress
Kim KH, Son JM, Benayoun BA, Lee C · 2018
Cited in: Effectiveness · how it works
View study[7]Increased expression of the mitochondrial derived peptide, MOTS-c, in skeletal muscle of healthy aging men is associated with myofiber composition
D'Souza RF, Woodhead JST, Hedges CP, Zeng N, Wan J, Kumagai H, Lee C, Cohen P, Cameron-Smith D, Mitchell CJ, Merry TL · 2020
Cited in: Is this right for me, FAQ
View study[8]MOTS-c is an effective target for treating cancer-induced bone pain through the induction of AMPK-mediated mitochondrial biogenesis
Yang L, Li M, Liu Y, Bai Y, Yin T, Chen Y, Jiang J, Liu S · 2024
Cited in: Safety
View study[9]Cellular and Molecular Mechanisms of Metformin Action
LaMoia TE, Shulman GI · 2021
Cited in: FAQ
View studyMyristoyl Pentapeptide-176 studies
View page[1]Open clinical trial evaluating efficacy of a peptide and glycosaminoglycan-based eyelash enhancer
Fernandez-Gonzalez P, et al. · 2024
View study[2]AP collagen peptides promote hair growth by activating the GSK-3β/β-catenin pathway
Lee JO, et al. · 2024
View study[3]Low molecular weight collagen peptide promotes hair growth by activating Wnt/GSK-3β/β-catenin signaling
Kim Y, et al. · 2024
View study[4]Hair growth promoting activity of keratin extract applied topically
Akanda MR, et al. · 2017
View study[5]Combination of biomimetic peptide and plant extract for modulation of alopecia
Loing E, et al. · 2013
View study[6]Myristoyl Pentapeptide-17 (SymPeptide 226EL) cosmetic ingredient profile
Cosmetic Ingredients Guide · 2024
Cited in: Dosing
View studyN-Acetyl Selank6 studies
View page[1]Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity
Vyunova TV, Andreeva L, Shevchenko K, et al. · 2018
Cited in: Dosing
View study[2]GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells
Filatova EV, Shadrina MI, Slominsky PA · 2017
View study[3]Selank Enhances the Effect of Diazepam: GABAA Receptor Subunit Study
Kasian A, Kube E, Bhatt D · 2017
View study[4]Selank Protects Against Ethanol-Induced Memory Impairment by Regulating BDNF Content
Kolik LG, Nadorova AV, Antipova TA, et al. · 2019
View study[5]Functional Connectomics of Selank: Brain Network Changes Associated with Anxiolytic Peptide Administration
Panikratova YR, Lebedeva IS, Sokolov OY, Rumshiskaya AD, Kupriyanov DA, Kost NV, Myasoedov NF · 2020
View study[6]Rapid and slow response during treatment of generalized anxiety disorder with peptide anxiolytic Selank
Medvedev VE, et al. · 2012
Cited in: Dosing
View studyN-Acetyl Semax Amidate6 studies
View page[1]Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain
Dolotov OV, Karpenko EA, Seredenina TS, et al. · 2006
Cited in: Dosing
View study[2]Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats
Filippenkov IB, Stavchansky VV, Denisova AE · 2020
View study[3]Brain Protein Expression Profile Confirms the Protective Effect of ACTH(4-7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion
Sudarkina OY, Filippenkov IB, Stavchansky VV · 2021
View study[4]The Efficacy of Semax in the Treatment of Patients at Different Stages of Ischemic Stroke
Gusev EI, Martynov MY, Kostenko EV · 2018
View study[5]The Effect of Semax and its C-end Peptide PGP on Expression of Neurotrophins and Their Receptors in Rat Brain During Incomplete Global Ischemia
Stavchansky VV, Tvorogova TV, Botsina AIu · 2011
View study[6]A nootropic adrenocorticotropin analog 4-10-Semax (15 years experience in its design and study)
Ashmarin IP, Nezavibatko VN, Myasoedov NF, et al. · 1997
Cited in: Dosing
View studyNAD+6 studies
View page[1]NAD+ precursor supplementation in human ageing: clinical evidence and challenges
Vinten KT, Trætowicz MM, Coskun E · 2025
Cited in: Dosing
View study[2]Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial
Yu X, Xu J, Cao J · 2026
View study[3]NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease
Berven H, Kverneng S, Sheard E · 2023
View study[4]Safety and Tolerability of Nicotinamide Riboside in Heart Failure With Reduced Ejection Fraction
Wang DD, Airhart SE, Zhou B · 2022
Cited in: Dosing
View study[5]Effects of NAD+ supplementation with oral nicotinamide riboside on vascular health and cognitive function in older adults with peripheral artery disease
Szarvas Z, Reyff ZA, Peterfi A · 2025
View study[6]Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study
Reyna K, et al. · 2026
Cited in: Dosing
View studyNafarelin4 studies
View page[1][2]Depressive symptoms associated with gonadotropin-releasing hormone agonists
Warnock JK, et al. · 1998
View study[3][4]SYNAREL (nafarelin acetate) nasal solution - FDA Prescribing Information / Dosage and Administration
Pfizer / U.S. FDA · 2017
View studyNatriuretic Peptide (ANP)4 studies
View page[1]Effect of low-dose administration of carperitide for acute heart failure: the LASCAR-AHF trial
Honda S, Nagai T, Honda Y, et al. · 2025
View study[2]Predictors of a Good Diuretic Response and Administration Methods for Carperitide in Patients With Acute Heart Failure
Inamoto M, Kohyama N, Suzuki H, et al. · 2024
View study[3]The Genetic Polymorphisms of NPPA:rs5065 and NPPB:rs198389 and Intermediate Phenotypes of Heart Failure in Polish Patients
Gorący-Rosik A, Fic M, Rosik J, et al. · 2025
View study[4]Effect of carperitide on the 1-year prognosis of patients with acute decompensated heart failure (JCS guideline dosing 0.0125-0.050 mcg/kg/min)
Nogi K, et al. · 2022
Cited in: Dosing
View studyNesiritide (BNP)5 studies
View page[1][2]Effect of Nesiritide in Patients with Acute Decompensated Heart Failure
O'Connor CM, et al. · 2011
View study[3][5]FDA Drug Approval: Natrecor (Nesiritide) NDA #20-920 Label
U.S. Food and Drug Administration · 2001
Cited in: Dosing
View study[6]Natrecor (nesiritide) FUSION II / clinical dosing review: 2 mcg/kg bolus then 0.01 mcg/kg/min infusion
Burnett JC Jr, Korinek J · 2008
Cited in: Dosing
View studyNisin5 studies
View page[1]Nisin, a novel lantibiotic: structure, biosynthesis and mechanism of antimicrobial activity
Lubelski J, Rink R, Khusainov R, Moll GN, Kuipers OP · 2008
View study[2]Nisin and its application in the food industry: a review
Gharsallaoui A, Oulahal N, Joly C, Degraeve P · 2016
View study[3]Anticancer activity of nisin against breast cancer cells
Joo NE, Ritchie K, Kamarajan P, Miao D, Kapila YL · 2012
View study[4]Nisin resistance in gram-positive bacteria: mechanisms and strategies for overcoming resistance
Zhou H, Fang J, Tian Y, Lu XY · 2014
View study[5]Nisin-biogel against Staphylococcus aureus isolates from diabetic foot infections (topical antimicrobial concentrations)
Jesus C, Soares R, Cunha E, Grilo M, Tavares L, Oliveira M · 2021
Cited in: Dosing
View studyNoopept (Omberacetam)6 studies
View page[1]Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation
Ostrovskaya RU, Vakhitova YV, Kuzmina USh · 2014
View study[2]GVS-111 prevents oxidative damage and apoptosis in normal and Down's syndrome human cortical neurons
Pelsman A, Hoyo-Vadillo C, Gudasheva TA · 2003
View study[3]Noopept efficiency in experimental Alzheimer disease: cognitive deficiency caused by beta-amyloid25-35 injection into Meynert basal nuclei of rats
Ostrovskaya RU, Belnik AP, Storozheva ZI · 2008
View study[4]Physicochemical and structural analysis of N-phenylacetyl-L-prolylglycine ethyl ester (Noopept) — an active pharmaceutical ingredient with nootropic activity
Araj SK, Szeleszczuk Ł, Gubica T · 2025
View study[5]Behavioral and electrophysiological analysis of the choline-positive effect of nootropic dipeptide acylproline (GVS-111)
Ostrovskaya RU, Mirzoev TKh, Firova FA · 2001
View study[6]A comparative study of noopept and piracetam in the treatment of mild and moderate cognitive impairment (Noopept 10 mg twice daily, 56 days)
Neznamov GG, Teleshova ES · 2009
Cited in: Dosing
View studyOrforglipron6 studies
View page[1]Orforglipron (LY3502970): A Phase 1a study in healthy participants
Knop FK, Benson CT, Skarsgard JK, et al. · 2023
View study[2]Orforglipron (LY3502970): A Phase 1b study in people with type 2 diabetes
Pratt E, Ma X, Liu R, et al. · 2023
View study[3]Orforglipron: A Novel Oral GLP-1 Agonist for Obesity and Diabetes
Pillai AA, Sharma AM, Krayem H, et al. · 2025
View study[4]Efficacy and Safety of Oral GLP-1 RA Orforglipron: A Systematic Review and Meta-Analysis
Hammad N, Ramadan AM, Nazmy A, et al. · 2026
View study[5]Efficacy and safety of danuglipron and orforglipron: a systematic review and meta-analysis
Zhou J, Wang F, Li S, et al. · 2025
View study[6]Orforglipron, an oral small-molecule GLP-1 receptor agonist, for obesity (ATTAIN-1 phase 3; 6, 12, 36 mg once daily)
Lilly ATTAIN-1 / NEJM · 2025
Cited in: Dosing
View studyOvagen5 studies
View page[1]The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology
Kuznik BI, Khasanova NB, Ryzhak GA, Mezsheriakova IE, Khavinson VK · 2020
View study[2][3]Antioxidant properties of geroprotective peptides of the pineal gland
Kozina LS, Arutjunyan AV, Khavinson VKh · 2007
View study[4]Short cell-penetrating peptides: a model of interactions with gene promoter sites
Khavinson VKh, Tarnovskaya SI, Linkova NS · 2013
View study[5]Molecular Aspects of Anti-aging Effect of Short Peptides
Khavinson VK, Linkova NS, Tarnovskaya SI · 2021
View studyOxytocin Acetate7 studies
View page[1]The neurobiological impact of oxytocin in mental health disorders: a comprehensive review
Chaulagain RP, Shrestha Y, Shrestha H · 2025
View study[2]Oxytocin in neurodevelopmental disorders: Autism spectrum disorder and Prader-Willi syndrome
Josselsohn A, Zhao Y, Espinoza D · 2024
View study[3]Role of Oxytocin in Different Neuropsychiatric, Neurodegenerative, and Neurodevelopmental Disorders
Ghazy AA, Soliman OA, Elbahnasi AI · 2023
View study[4]Effects of Intranasal Administration of Oxytocin and Vasopressin on Social Cognition and Potential Routes and Mechanisms of Action
Yao S, Kendrick KM · 2022
View study[5]Oxytocin and brain activity in humans: A systematic review and coordinate-based meta-analysis of functional MRI studies
Grace SA, Rossell SL, Heinrichs M · 2018
View study[6]Dose-dependent social-cognitive effects of intranasal oxytocin (8 IU and 24 IU) in adults with ASD
Quintana DS, et al. · 2017
Cited in: Dosing
View study[7]Oxytocin (Pitocin) Dosage Guide — IV infusion for labor induction (0.5-1 milliunits/min initial)
Drugs.com / FDA prescribing information · 2024
Cited in: Dosing
View studyP21 (P021)4 studies
View page[1]Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice
Li B, Wanka L, Blanchard J, Liu F, Bhatt D, Bhatt S, Bhatt A, Bhatt DK, Bhatt RS, Bhatt SP, Bhatt CK, Iqbal K, Bhatt S · 2010
View study[2]Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease
Kazim SF, Blanchard J, Dai CL, Bhatt A, Martinez-Martin MC, Bhatt DK, Bhatt SP, Bhatt CK, Bhatt RS, Bhatt S, Iqbal K · 2014
View study[3]Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease
Kazim SF, Iqbal K · 2016
View study[4]Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound
Baazaoui N, Flory M, Bhatt DK, Bhatt SP, Iqbal K · 2017
View studyPACAP-388 studies
View page[1]More Than Three Decades After Discovery of the Neuroprotective Effect of PACAP, What Is Still Preventing Its Clinical Use?
Cherait A, et al. · 2025
View study[2][3]Effect of Lu AG09222 on PACAP38-induced vasodilation, heart rate increase, and headache in healthy subjects
Rasmussen NB, et al. · 2023
View study[4]PACAP glycosides promote cell outgrowth and reduce infarct size after stroke in preclinical model
Bernard K, et al. · 2024
View study[5]Intranasal PACAP reduces infarct volume and promotes functional recovery after middle cerebral artery occlusion
Cherait A, et al. · 2020
View study[6]The effect of intravenous PACAP38 on cerebral hemodynamics in healthy volunteers
Birk S, Sitarz JT, Petersen KA, Oturai PS, Kruuse C, Fahrenkrug J, Olesen J · 2007
Cited in: Dosing
View study[7]Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers
Amin FM, Asghar MS, Guo S, Hougaard A, Hansen AE, Schytz HW, et al. · 2012
Cited in: Dosing
View study[8]Hypersensitivity to PACAP-38 in post-traumatic headache: a randomized clinical trial
Al-Khazali HM, Christensen RH, Dodick DW, et al. · 2024
Cited in: Dosing
View studyPalmitoyl Oligopeptide6 studies
View page[1]Noninvasive monitoring of palmitoyl hexapeptide-12 in human skin layers: mechanical interaction and skincare benefits
Ligorio C, et al. · 2025
View study[2]Self-assembly of short biopeptides onto skin tissue components studied using QCM-D
Murthy NS, et al. · 2025
View study[3]Synergistic effects of injectable platelet-rich fibrin and bioactive peptides on dermal fibroblast viability and ECM gene expression
Paccola AGL, et al. · 2025
View study[4]Bioactive peptides in cosmetic formulations: review of current in vitro and ex vivo evidence
van Walraven N, et al. · 2025
View study[5]Matrikines in the skin: origin, effects, and therapeutic potential
Sirois JP, et al. · 2024
View study[6]Safety Assessment of Tripeptide-1, Palmitoyl Tripeptide-1, and Related Palmitoyl Peptides as Used in Cosmetics
Johnson W et al., Cosmetic Ingredient Review (CIR) Expert Panel · 2018
Cited in: Dosing
View studyPalmitoyl Pentapeptide-4 (Matrixyl)6 studies
View page[1]Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin
Robinson LR, et al. · 2005
Cited in: Dosing
View study[2]Liposome encapsulation of the Palmitoyl-KTTKS peptide: structural and functional characterization
Vitali A, et al. · 2024
View study[3]Dermal stability and in vitro skin permeation of collagen pentapeptides (KTTKS and palmitoyl-KTTKS)
Choi YL, et al. · 2014
View study[4]Liquid chromatography-tandem mass spectrometry to determine the stability of collagen pentapeptide (KTTKS) in rat skin
Park EJ, et al. · 2012
View study[5]Synergistic effects of injectable platelet-rich fibrin and bioactive peptides on dermal fibroblast viability and ECM gene expression
Paccola AGL, et al. · 2025
View study[6]Safety Assessment of Pentapeptide Ingredients as Used in Cosmetics
Cosmetic Ingredient Review (CIR) Expert Panel · 2018
Cited in: Dosing
View studyPalmitoyl Tetrapeptide-76 studies
View page[1]Peptide Bioregulation of Aging: Results and Prospects
Khavinson VK, Linkova NS, Pronyaeva VE · 2022
View study[2]Anti-inflammatory bioactive peptide alleviates skin inflammation by inhibiting the NF-κB signaling pathway
Guo Z, et al. · 2025
View study[3]Key molecular regulators in skin regeneration: PPARG, VEGFA, BGLAP, and IL6
Tolentino JC, et al. · 2026
View study[4]Acetyl Hexapeptide-8 in cosmeceuticals — a review of skin permeability and efficacy
Zdrada-Nowak J, et al. · 2025
View study[5]Current approaches in cosmeceuticals: peptides, biotics and marine biopolymers
Badilli U, et al. · 2025
View study[6]Safety Assessment of Tripeptide-1, Palmitoyl Tripeptide-1, and Related Palmitoyl Peptides as Used in Cosmetics
Johnson W et al., Cosmetic Ingredient Review (CIR) Expert Panel · 2018
Cited in: Dosing
View studyPalmitoyl Tripeptide-16 studies
View page[1]Comprehensive evaluation of the efficacy and safety of a new multi-component anti-aging topical eye cream
Yang F, et al. · 2024
View study[2]Topically applied GHK as an anti-wrinkle peptide: advantages, problems and prospective
Mortazavi SM, et al. · 2025
View study[3]The naturally occurring peptide GHK reverses age-related fibrosis by modulating myofibroblast function
He Q, et al. · 2024
View study[4]Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data
Pickart L, Margolina A · 2018
View study[5]GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration
Pickart L, et al. · 2015
View study[6]Safety Assessment of Tripeptide-1, Palmitoyl Tripeptide-1, and Related Palmitoyl Peptides as Used in Cosmetics
Johnson W et al., Cosmetic Ingredient Review (CIR) Expert Panel · 2018
Cited in: Dosing
View studyPancragen5 studies
View page[1]Effects of pancragen on the differentiation of pancreatic cells during their ageing
Khavinson VKh, Durnova AO, Polyakova VO, Tolibova GH, Linkova NS, Kvetnoy IM, Kvetnaia TV · 2013
View study[2]Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys
Goncharova ND, Ivanova LG, Oganyan TE · 2015
View study[3]The tetrapeptide Pankragen Forte efficiency in elderly people with prediabetic state
Korkushko OV, Chizhova VP, Shatilo VB · 2013
Cited in: Dosing
View study[4]Impact of tetrapeptide Pancragen on endocrine function of the pancreas in old monkeys
Goncharova ND, Ivanova LG, Oganian TE · 2014
View study[5]PEG-MGF6 studies
View page[1]Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages
Kandalla PK, Goldspink G, Butler-Browne G, Mouly V · 2011
Cited in: Dosing
View study[2]Expression and splicing of the insulin-like growth factor gene in rodent muscle is associated with muscle satellite (stem) cell activation following local tissue damage
Hill M, Goldspink G · 2003
Cited in: Dosing
View study[3]Sustained delivery of MGF peptide from microrods attracts stem cells and reduces apoptosis of myocytes
Doroudian G, Pinney J, Ayala P, et al. · 2014
View study[4]Mechano growth factor E peptide promotes osteoblasts proliferation and bone-defect healing in rabbits
Deng M, Zhang B, Wang K, et al. · 2011
View study[5]Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise
Hameed M, Orrell RW, Cobbold M, Goldspink G, Harridge SD · 2003
View study[6]PEG-MGF Protocol — Dosing and Administration (community practice reference)
Peptide Initiative · 2025
Cited in: Dosing
View studyPemvidutide7 studies
View page[1]Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study
Noureddin M, et al. · 2025
View study[2]Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial
Browne SK, et al. · 2025
View study[3]Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study
Harrison SA, et al. · 2025
View study[4]Metabolic dysfunction-associated steatohepatitis treatment: spotlight on the latest hepatoprotective drugs
Kaya E, et al. · 2025
View study[5]Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis
Nestor JJ, et al. · 2022
View study[6]262-OR: Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, in Subjects with Overweight or Obesity - A 48-Week, Placebo-Controlled, Phase 2 (MOMENTUM) Trial
Aronne L, Harris MS, Roberts MS, Suschak JJ, Tomah S, Kasper J, He L, Yang J, Frias JP, Browne SK · 2024
Cited in: Dosing
View study[7]Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH
Altimmune, Inc. · 2025
Cited in: Dosing
View studyPentadecapeptide (BPC Analog)5 studies
View page[1]Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing
McGuire FP, et al. · 2025
Cited in: Dosing
View study[2]Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
Vasireddi N, et al. · 2025
Cited in: Dosing
View study[3]Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing
Gwyer D, et al. · 2019
Cited in: Dosing
View study[4]Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro
Huang T, et al. · 2015
View study[5]Pidotimod6 studies
View page[1]Reappraisal of Pidotimod: an immunomodulatory agent with 30-year evidence
Marseglia GL, Gelardi M, Santus P · 2024
View study[2]Pidotimod in pediatrics: new evidence and future perspectives
Ciprandi G, Marseglia GL · 2024
Cited in: Dosing
View study[3]Pidotimod and Immunological Activation in Individuals Infected with HIV
Ucciferri C, Falasca K, Reale M · 2021
View study[4]Analysis of Factors and T-Lymphocyte Subset Changes in Pediatric Recurrent Respiratory Infections Post-Pidotimod Treatment
Hu R, Jin C, Lin X · 2025
View study[5][6]Pidotimod: the immunomodulatory agent - an in-depth review of current evidence
Ferrario BE, Garuti S, Braido F, Canonica GW · 2015
Cited in: Dosing
View studyPinealon6 studies
View page[1]Molecular Mechanisms of Action of Short Peptides for the Treatment of Alzheimer's Disease
Khavinson V, Linkova N, Kozhevnikova E · 2021
View study[2]Molecular Basis of Specific Interaction of Short Peptides with DNA
Khavinson VK, Tendler SM, Vanyushin BF · 2014
View study[3]Tripeptides Restore the Number of Neuronal Spines under Conditions of In Vitro Modeled Alzheimer's Disease
Kraskovskaya NA, Kukanova EO, Lin'kova NS · 2017
View study[4]Neuroprotective Properties of Short Peptides on the Model of Early Huntington's Disease
Khavinson V, Lin'kova NS, Kukanova EO · 2019
View study[5]Short Peptides Stimulate Serotonin Expression in Cells of Brain Cortex
Khavinson V, Lin'kova NS, Tarnovskaya SI · 2014
View study[6]Encapsulated Delivery of Regulatory (EDR) Peptide Pinealon: Review
Khavinson et al. · 2021
Cited in: Dosing
View studyPNC-275 studies
View page[1]PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis
Sarafraz-Yazdi E, Mumin S, Engel D, et al. · 2022
View study[2]Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells
Thadi A, Forber M, Engel D, et al. · 2020
View study[3]Molecular Targeting of H/MDM-2 Oncoprotein in Human Colon Cancer Cells and Stem-like Colonic Epithelial-derived Progenitor Cells
Thadi A, Esposito M, Bhargava S, et al. · 2021
View study[4]The Anti-Cancer Peptide, PNC-27, Induces Tumor Cell Lysis as the Intact Peptide
Bowne WB, Michl J, Sookraj KA, et al. · 2014
View study[5]Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes
Sookraj KA, Bowne WB, Adler V, et al. · 2010
View studyPolymyxin B6 studies
View page[1]Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications
Zavascki AP, Goldani LZ, Li J, Nation RL · 2007
View study[2]Nephrotoxicity associated with intravenous polymyxin B: a systematic review and meta-analysis
Rigatto MH, Behle TF, Falci DR, Freitas T, Lopes NT, Nunes M · 2015
View study[3]Therapeutic drug monitoring of polymyxin B: target exposure and optimal dosing strategies
Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A · 2019
Cited in: Dosing
View study[4]Polymyxin B for the treatment of multidrug-resistant Gram-negative infections: clinical outcomes and resistance mechanisms
Elias LS, Konzen D, Krebs JM, Zavascki AP · 2010
View study[5]Polymyxin combination therapy for carbapenem-resistant organisms: systematic review and network meta-analysis
Ni W, Han Y, Liu J, Wei C, Zhao J, Cui J, Wang R, Liu Y · 2022
View study[6]Polymyxin B Sulfate for Injection USP - FDA Prescribing Information (DailyMed)
X-Gen Pharmaceuticals · 2012
Cited in: Dosing
View studyPralmorelin (GHRP-2)4 studies
View page[1]Clinical Usefulness of the Growth Hormone-Releasing Peptide-2 Test for Hypothalamic-Pituitary Disorder.
Suzuki S, Ruike Y, Ishiwata K, et al. · 2022
Cited in: Dosing
View study[2]Robust growth hormone responses to GH-releasing peptide 2 in adolescents.
Onuki T, Hiroaki T, Sawano K, et al. · 2024
View study[3]Growth Hormone-Releasing Peptide 2 May Be Associated With Decreased M1 Macrophage Production and Increased Tendon-Bone Healing in Rat Rotator Cuff Model.
Li Y, Yao L, Zhang C, et al. · 2025
View study[4]GHRP-2, like ghrelin, increases food intake in healthy men
Laferrere B, Abraham C, Russell CD, Bowers CY · 2005
Cited in: Dosing
View studyPramlintide6 studies
View page[1]Pramlintide as an Adjunct to Insulin Therapy in Type 2 Diabetes: Systematic Review and Meta-Analysis
Singh-Franco D, Perez A, Harrington C · 2024
View study[2]Pramlintide for the Treatment of Type 1 and Type 2 Diabetes Mellitus
Younk LM, Mikeladze M, Davis SN · 2011
View study[3]Amylin Physiology and Its Role in Diabetes Management
Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD · 2015
View study[4]Pramlintide: A Review of Its Use in the Management of Insulin-Requiring Diabetes Mellitus
Ryan GJ, Jobe LJ, Martin R · 2005
View study[5]Pramlintide Acetate: An Adjunctive Therapy for Type 1 and Type 2 Diabetes
Schmitz O, Brock B, Rungby J · 2004
View study[6]SYMLIN (pramlintide acetate) injection - FDA Prescribing Information (DailyMed)
AstraZeneca Pharmaceuticals · 2015
Cited in: Dosing
View studyProstamax6 studies
View page[1]Bioregulator Peptides and Prostatic Function in Aging Males
Khavinson VK, Ryzhak GA · 2012
Cited in: Dosing
View study[2][3]Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line
Avolio F, Martinotti S, Khavinson VK · 2022
View study[4]Peptide Regulation of Gene Expression and Protein Synthesis in Organotypic Cultures
Khavinson VK, Linkova NS, Kvetnoy IM · 2013
View study[5][6]Agent possessing prostatotropic activity (KEDP peptide) - Patent RU2177802C1
Khavinson V.Kh. et al. · 2002
Cited in: Dosing
View studyPT-141 (Bremelanotide)6 studies
View page[1]Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
Kingsberg SA, Clayton AH, Portman D · 2019
Cited in: Dosing
View study[2]Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder
Simon JA, Kingsberg SA, Portman D · 2019
View study[3][4]The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women
Pfaus JG, Sadiq A, Spana C · 2022
View study[5]The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results
Koochaki P, Revicki D, Wilson H · 2021
View study[6]VYLEESI (bremelanotide injection) US Prescribing Information
AMAG Pharmaceuticals (FDA) · 2019
Cited in: Dosing
View studyRelaxin-2 (Serelaxin)5 studies
View page[1]End-organ protective effect of serelaxin in patients hospitalized for heart failure: Results of the biomarker substudy of Relaxin in Acute Heart Failure-2 (RELAX-AHF-2)
Voors AA, et al. · 2025
View study[2]Relaxin and the Cardiovascular System: from Basic Science to Clinical Practice
Martins RC, et al. · 2020
View study[3]Effects of Serelaxin in Patients with Acute Heart Failure
Metra M, et al. · 2019
Cited in: Dosing
View study[4]Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHF-EU
Maggioni AP, et al. · 2019
View study[5]Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial
Teerlink JR, Cotter G, Davison BA, et al. · 2013
Cited in: Dosing
View studyRetatrutide14 studies
View page[1]Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frías JP et al. · 2023
Cited in: Is this right for me, Dosing, FAQ, Safety, Safety · side effects, Effectiveness · timeline, Effectiveness · troubleshooting, Hero
View study[2]A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity
Kaur M, Misra S · 2024
Cited in: FAQ, Effectiveness · how it works, Dosing · timing, Hero
View study[3]Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis
Tewari J, Qidwai KA, Tewari A et al. · 2025
Cited in: Dosing, Safety, Safety · side effects, Effectiveness · troubleshooting
View study[4]Effects of retatrutide on body composition in people with type 2 diabetes
Coskun T, Wu Q, Schloot NC et al. · 2025
Cited in: Effectiveness · timeline
View study[5]Triple Agonism Based Therapies for Obesity
Goldney J, Hamza M, Surti F · 2025
Cited in: Is this right for me
View study[6]Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Rosenstock J, Frias J, Jastreboff AM et al. · 2023
Cited in: Is this right for me, Safety, Dosing · timing
View study[7]Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
Sanyal AJ, Kaplan LM, Frias JP et al. · 2024
Cited in: Is this right for me
View study[8]Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss
Sodhi M, Rezaeianzadeh R, Kezouh A et al. · 2023
Cited in: Safety · side effects
View study[9]Gallstone formation during weight-reduction dieting
Liddle RA, Goldstein RB, Saxton J · 1989
Cited in: Safety · side effects
View study[10]Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN et al. · 2022
Cited in: FAQ
View study[11]Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials
Giblin K, Kaplan LM, Somers VK et al. · 2025
Cited in: FAQ
View study[12]Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
Wilding JPH, Batterham RL, Davies M et al. · 2022
Cited in: FAQ
View study[13]Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation
Bjerre Knudsen L, Madsen LW, Andersen S et al. · 2010
Cited in: FAQ
View study[14]Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
Wilding JPH, Batterham RL, Calanna S, et al. · 2021
Cited in: FAQ
View studySelank7 studies
View page[1]Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity
Vyunova TV, Andreeva L, Shevchenko K, et al. · 2018
Cited in: Dosing · adjustment, Is this right for me, Effectiveness · signs, FAQ, Safety, Effectiveness · how it works, Effectiveness · timeline, Hero
View study[2]Selank Protects Against Ethanol-Induced Memory Impairment by Regulating BDNF Content
Kolik LG, Nadorova AV, Antipova TA, et al. · 2019
Cited in: Is this right for me, Effectiveness · how it works
View study[3]A Comparison of the Anxiolytic Effect and Tolerability of Selank and Phenazepam
Medvedev VE, Tereshchenko ON, Israelian AIu, et al. · 2014
Cited in: Dosing, FAQ, Safety, Effectiveness · timeline
View study[4]Expression of Inflammation-Related Genes in Mouse Spleen Under Tuftsin Analog Selank
Kolomin T, Shadrina M, Andreeva L, et al. · 2011
Cited in: Is this right for me, Effectiveness · how it works, Hero
View study[5]Immunomodulatory Effects of Selank in Patients with Anxiety-Asthenic Disorders
Uchakina ON, Uchakin PN, Miasoedov NF, et al. · 2008
Cited in: Dosing, Safety, Effectiveness · how it works
View study[6]The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity
Zozulya AA, Kost NV, Sokolov OY, et al. · 2001
Cited in: Effectiveness · how it works
View study[7]Changes in expression of the genes for chemokines, cytokines, and their receptors in response to selank and its fragments
Kolomin TA, Shadrina MI, Slominsky PA, et al. · 2011
Cited in: Effectiveness · how it works
View studySemaglutide6 studies
View page[1]Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
Wilding JPH, Batterham RL, Calanna S, et al. · 2021
View study[2]Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. · 2023
View study[3]Semaglutide from Bench to Bedside: The Experimental Journey
Weiskirchen R, Lonardo A · 2025
View study[4]Tirzepatide vs. Semaglutide: Clinical Decision-Making in the GLP-1 Landscape
Mondoh A, Crotty M, le Roux CW · 2025
View study[5]OZEMPIC (semaglutide injection) Prescribing Information
Novo Nordisk / U.S. FDA · 2025
Cited in: Dosing
View study[6]RYBELSUS (oral semaglutide tablets) Prescribing Information
Novo Nordisk / U.S. FDA · 2024
Cited in: Dosing
View studySemax5 studies
View page[1]Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus
Dolotov OV, Karpenko EA, Inozemtseva LS, et al. · 2006
Cited in: Dosing
View study[2]Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain
Dolotov OV, Karpenko EA, Seredenina TS, et al. · 2006
Cited in: Dosing
View study[3]Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action
Shadrina M, Kolomin T, Agapova T, et al. · 2010
Cited in: Dosing
View study[4]Semax, an ACTH4-10 peptide analog with high affinity for copper(II) ion and protective ability against metal induced cell toxicity
Tabbi G, Magri A, Giuffrida A, et al. · 2015
View study[5]The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease
Radchenko AI, Kuzubova EV, Apostol AA · 2025
View studySermorelin5 studies
View page[1]Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men
Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR · 1992
Cited in: Dosing
View study[2]Endocrine and metabolic effects of long-term administration of GHRH-(1-29)-NH2 in age-advanced men and women
Khorram O, Laughlin GA, Yen SS · 1997
Cited in: Dosing
View study[3]Effects of single nightly injections of GHRH (1-29) in healthy elderly men
Vittone J, Blackman MR, Busby-Whitehead J, et al. · 1997
Cited in: Dosing
View study[4]In vivo semiquantification of hypothalamic GHRH output in humans: evidence for relative GHRH deficiency in aging
Russell-Aulet M, Jaffe CA, Demott-Friberg R, Barkan AL · 1999
View study[5]Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum IGF-1 Levels
Sigalos JT, Pastuszak AW, Allison A, Khera M · 2017
View studySetmelanotide6 studies
View page[1][2]Setmelanotide in patients aged 2-5 years with rare MC4R pathway-associated obesity (VENTURE)
Argente J, Verge CF, Okorie U, et al. · 2025
Cited in: Dosing
View study[3]Setmelanotide: A Melanocortin-4 Receptor Agonist for Severe Obesity Due to Hypothalamic Dysfunction
Qamar S, Mallik R, Makaronidis J, et al. · 2024
Cited in: Dosing
View study[4]The effect of MC4R agonist drugs on obesity and metabolic risk factors: a systematic review and meta-analysis
Sun Y, Abed M, Sohouli MH, et al. · 2025
View study[5]Setmelanotide-mediated MC4R activation improves hypothalamic obesity via CaMKK2/AMPK pathways
Peng J, Ou Y, Zhou M, et al. · 2025
View study[6]IMCIVREE (setmelanotide injection) US Prescribing Information
Rhythm Pharmaceuticals (FDA / DailyMed) · 2024
Cited in: Dosing
View studySLU-PP-3324 studies
View page[1]Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity
Billon C, Sitaula S, Banerjee S, et al. · 2023
Cited in: Dosing
View study[2]A Synthetic ERR Agonist Alleviates Metabolic Syndrome
Billon C, Schoepke E, Avdagic A, et al. · 2024
Cited in: Dosing
View study[3]An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity
Billon C, Appourchaux K, Côté I, et al. · 2025
View study[4]The Estrogen Receptor-Related Orphan Receptors Regulate Autophagy through TFEB
Losby M, Hayes M, Valfort A, et al. · 2024
View studySM-1306863 studies
View page[1]Pharmacological profile of a new orally active growth hormone secretagogue, SM-130686
Nagamine J et al. · 2001
View study[2]Synthesis and pharmacological profile of SM-130686 and related compounds
Nagamine J et al. · 2006
View study[3]Common structural basis for constitutive activity of the ghrelin receptor family
Holst B et al. · 2009
View studySnap-85 studies
View page[1]Non-Invasive Peptides as the Future of Botox Alternatives
Cosmetics MDPI Review · 2024
Cited in: Dosing
View study[2]Clinical Safety and Efficacy Evaluation of a Dissolving Microneedle Patch Having Dual Anti-Wrinkle Effects
Park JH, et al. · 2024
View study[3]Topical delivery of acetyl hexapeptide-8 from different emulsions
Hoppel M, Reznicek G, Kahlig H · 2015
View study[4]In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation
Kraeling ME, Zhou W, Wang P · 2015
View study[5]Public Interest in Acetyl Hexapeptide-8: Longitudinal Analysis
Olsson SE, Sreepad B, Lee T · 2024
View studySS-31 (Elamipretide)16 studies
View page[1]Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential
Tung C, Varzideh F, Farroni E · 2025
Cited in: Is this right for me, FAQ, Safety, Effectiveness · how it works, Dosing · timing, Hero
View study[2]Mitochondrial protein interaction landscape of SS-31
Chavez JD, Tang X, Campbell MD · 2020
Cited in: Is this right for me, FAQ, Effectiveness · how it works
View study[3]Structure-activity relationships of mitochondria-targeted tetrapeptide pharmacological compounds
Mitchell W, Tamucci JD, Ng EL · 2022
Cited in: FAQ, Effectiveness · how it works
View study[4]SS-31: A promising therapeutic agent against bleomycin-induced pulmonary fibrosis in Mice
Gu Q, Wang Y, Zhang H · 2025
View study[5]Mitochondrial Cardiolipin-Targeted Tetrapeptide, SS-31, Exerts Neuroprotective Effects Within In Vitro and In Vivo Models of Spinal Cord Injury
Ravenscraft B, Lee DH, Dai H · 2025
Cited in: FAQ, Effectiveness · how it works
View study[6]A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome
Reid Thompson W, Hornby B, Manuel R, et al. · 2021
Cited in: Dosing, Safety
View study[7]SS-31 (Elamipretide/Bendavia): mechanism, clinical pharmacology and intravenous dosing review
Cognitive Vitality (ADDF) · 2019
Cited in: Dosing, Safety · side effects
View study[8]FORZINITY (elamipretide) injection, for subcutaneous use - FDA prescribing information
U.S. Food and Drug Administration · 2025
Cited in: FAQ, Safety
View study[9]Stealth BioTherapeutics Announces FDA Accelerated Approval of FORZINITY (elamipretide HCl), the First Therapy for Barth Syndrome
Stealth BioTherapeutics · 2025
Cited in: FAQ, Safety
View study[10]Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial
Karaa A, Bertini E, Carelli V · 2023
Cited in: FAQ, Safety, Safety · side effects
View study[11]The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action
Mitchell W, Ng EA, Tamucci JD · 2020
Cited in: Effectiveness · how it works
View study[12]Cardiolipin, the Mitochondrial Signature Lipid: Implication in Cancer
Ahmadpour ST, Maheo K, Servais S · 2020
Cited in: Effectiveness · how it works
View study[13]Role of cardiolipin in skeletal muscle function and its therapeutic implications
Yoo Y, Yeon M, Yoon MS · 2025
Cited in: Effectiveness · how it works
View study[14]Interactions between mitochondrial dysfunction and other hallmarks of aging: Paving a path toward interventions that promote healthy old age
Li Y, Berliocchi L, Li Z · 2023
Cited in: Is this right for me
View study[15]SS-31 and NMN: Two paths to improve metabolism and function in aged hearts
Whitson JA, Bitto A, Zhang H · 2020
Cited in: Dosing · timing
View study[16]Pharmacological targeting of mitochondrial function and reactive oxygen species production prevents colon 26 cancer-induced cardiorespiratory muscle weakness
Smuder AJ, Roberts BM, Wiggs MP · 2020
Cited in: FAQ
View studySubstance P Antagonists5 studies
View page[1]Involvement of ASIC3 and Substance P in Therapeutic Ultrasound-Mediated Analgesia in Mouse Models of Fibromyalgia
Han DS, et al. · 2023
View study[2]Involvement of the substance P/neurokinin-1 receptor system in oral pain and inflammation
Velasco-Ortega E, et al. · 2020
View study[3]Advances in the research and application of neurokinin-1 receptor antagonists
Hong X, et al. · 2024
View study[4]Trigeminal nerve-driven neurogenic inflammation linking migraine to glioblastoma invasion: a literature review
Song X, et al. · 2025
View study[5]EMEND (aprepitant) capsules and EMEND for injection (fosaprepitant) Prescribing Information
Merck & Co. / U.S. FDA · 2010
Cited in: Dosing
View studySurvodutide5 studies
View page[1]Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
le Roux CW, Steen O, Lucas KJ, et al. · 2024
Cited in: Dosing
View study[2]Dose-response effects on HbA1c and bodyweight reduction of survodutide compared with placebo and open-label semaglutide in type 2 diabetes
Blüher M, Rosenstock J, Hoefler J, et al. · 2024
View study[3]BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
Zimmerman T, et al. · 2022
View study[4]Survodutide for the Treatment of Obesity: Design of the SYNCHRONIZE CVOT
Kosiborod MN, Platz E, Wharton S, et al. · 2024
View study[5]The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection
Thomas L, Martel E, Rist W, et al. · 2024
View studySYN-AKE6 studies
View page[1]Anti-aging activity of SYN-AKE peptide by in silico approaches and in vitro tests
Gok B, et al. · 2024
View study[2]Viper venom Botox: molecular origin and evolution of waglerin peptides used in anti-wrinkle skin cream
Debono J, et al. · 2017
View study[3]Real-world clinical experience with neuro-peptide serum in combination with botulinum toxin Type-A injections
Lupin M, et al. · 2024
View study[4]Residues in the epsilon subunit of nAChR interact to confer selectivity of waglerin-1 for the alpha-epsilon interface
Molles BE, et al. · 2002
View study[5]Waglerin-1 selectively blocks the epsilon form of the muscle nicotinic acetylcholine receptor
McArdle JJ, et al. · 1999
View study[6]SYN-AKE formulation guidelines and in-vivo efficacy data (4% use level)
DSM Personal Care · 2020
Cited in: Dosing
View studyTabimorelin3 studies
View page[1]The pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of NN703, a novel orally active growth hormone secretagogue in healthy male volunteers
Zdravkovic M, et al. · 2000
Cited in: Dosing
View study[2]Oral administration of NN703 in adult patients with growth hormone deficiency
Svensson J, et al. · 2003
Cited in: Dosing
View study[3]Pharmacokinetic and pharmacodynamic modeling of NN703 after a single oral dose to human volunteers
Agersø H, et al. · 2001
View studyTB-5006 studies
View page[1]Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications
Goldstein AL, Hannappel E, Sosne G · 2012
View study[2]Advances in the basic and clinical applications of thymosin beta4
Goldstein AL, Kleinman HK · 2015
View study[3]Neuroprotective and neurorestorative effects of thymosin beta4 treatment following experimental traumatic brain injury
Xiong Y, Mahmood A, Meng Y, et al. · 2012
View study[4][5]Thymosin beta4 promotes endothelial progenitor cell angiogenesis via a vascular endothelial growth factor-dependent mechanism
Zhao Y, Song J, Bi X, et al. · 2018
View study[6]TB-500 (Thymosin Beta-4) research-use dosing protocol and reconstitution guide
Peptide Dosing Protocols · 2026
Cited in: Dosing
View studyTesamorelin16 studies
View page[1]Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trials
Falutz J, Mamputu JC, Potvin D, et al. · 2010
Cited in: Dosing · adjustment, Is this right for me, Dosing, Effectiveness · signs, FAQ, Safety, Effectiveness · how it works, Effectiveness · timeline, Effectiveness · troubleshooting
View study[2]Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin
Stanley TL, Falutz J, Marsolais C, et al. · 2012
Cited in: Is this right for me, Effectiveness · signs, Effectiveness · timeline
View study[3]Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults
Baker LD, Barsness SM, Borson S, et al. · 2012
Cited in: FAQ, Effectiveness · how it works, Effectiveness · timeline
View study[4]Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial
Stanley TL, Fourman LT, Feldpausch MN, et al. · 2019
Cited in: Is this right for me
View study[5]Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy
Dhillon S · 2011
Cited in: Is this right for me, FAQ, Effectiveness · how it works, Effectiveness · timeline, Effectiveness · troubleshooting
View study[6]EGRIFTA SV (tesamorelin for injection) Prescribing Information
Theratechnologies Inc. / U.S. FDA · 2019
Cited in: Is this right for me, Dosing, FAQ, Safety, Effectiveness · how it works, Safety · side effects, Effectiveness · timeline, Safety · when to stop, Hero
View study[7]Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension
Falutz J, Potvin D, Mamputu JC, et al. · 2010
Cited in: FAQ, Effectiveness · timeline
View study[8]Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue
Ferdinandi ES, Brazeau P, High K, Procter B, Fennell S, Dubreuil P · 2007
Cited in: Effectiveness · how it works
View study[9]Growth hormone-releasing hormone receptor (GHRH-R) and its signaling
Halmos G, Szabo Z, Dobos N, Juhasz E, Schally AV · 2025
Cited in: Effectiveness · how it works
View study[10]Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies
Stanley TL, Grinspoon SK · 2015
Cited in: Is this right for me, FAQ, Effectiveness · how it works
View study[11]Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial
Makimura H, Feldpausch MN, Rope AM, Hemphill LC, Torriani M, Lee H, Grinspoon SK · 2012
Cited in: FAQ, Effectiveness · timeline
View study[12]Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement
Neeland IJ, Ross R, Despres JP, et al. · 2019
Cited in: Is this right for me
View study[13]The enigmatic role of growth hormone in age-related diseases, cognition, and longevity
Colon G, Saccon T, Schneider A, et al. · 2019
Cited in: Effectiveness · how it works
View study[14]Adult growth hormone deficiency - benefits, side effects, and risks of growth hormone replacement
Reed ML, Merriam GR, Kargi AY · 2013
Cited in: FAQ, Safety · side effects
View study[15]Human growth hormone receptor (GHR) expression in obesity: I. GHR mRNA expression in omental and subcutaneous adipose tissues of obese women
Erman A, Veilleux A, Tchernof A, Goodyer CG · 2011
Cited in: Effectiveness · how it works
View study[16]Exogenous 20K growth hormone (GH) suppresses endogenous 22K GH secretion in normal men
Hashimoto Y, Kamioka T, Hosaka M, Mabuchi K, Mizuchi A, Shimazaki Y, Tsunoo M, Tanaka T · 2000
Cited in: FAQ
View studyTestagen5 studies
View page[1]Peptide Bioregulation of Aging: Results and Prospects
Khavinson VK, Linkova NS, Pronyaeva VE · 2022
Cited in: Dosing
View study[2]Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line
Avolio F, Martinotti S, Khavinson VK · 2022
View study[3]Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's Disease
Khavinson VK, Lin'kova NS, Umnov RS · 2021
View study[4][5]Thymalin4 studies
View page[1]Thymalin: Immune modulation and therapeutic potential in aging
Khavinson VH, et al. · 2020
Cited in: Dosing
View study[2]Peptide thymus extract improves immune markers in chronic diseases
Loginova NN, et al. · 2018
View study[3][4]Thymopentin (TP-5)5 studies
View page[1]Thymopentin (TP-5) enhances immune function in HIV and cancer patients
Jiang Y, et al. · 2015
View study[2]Thymopentin modulates T cell receptor signaling and immune tolerance
Valone FH, et al. · 2017
View study[3]Thymopentin peptide in age-related immune decline and vaccination response
Provinciali M, et al. · 2019
View study[4][5]Safety and efficacy of thymopentin in zidovudine (AZT)-treated asymptomatic HIV-infected subjects with 200-500 CD4 cells/mm3: a double-blind placebo-controlled trial
Goldstein G, et al. · 1995
Cited in: Dosing
View studyThymopoietin5 studies
View page[1]Thymopoietin: The parent thymic hormone and its immune restoration properties
Goldstein G, et al. · 2015
View study[2]Thymopoietin peptide fragments enhance both cellular and humoral immunity
Hadden JW, et al. · 2016
View study[3]Thymopoietin restores T cell receptor-mediated signaling in aging
Sempowski GD, et al. · 2018
View study[4]Thymopoietin peptides in immune recovery during HIV and cancer treatment
Sereti I, et al. · 2017
View study[5]Safety and efficacy of thymopentin in zidovudine (AZT)-treated asymptomatic HIV-infected subjects with 200-500 CD4 cells/mm3: a double-blind placebo-controlled trial
Goldstein G, et al. · 1995
Cited in: Dosing
View studyThymosin Alpha-16 studies
View page[1]Historical review on thymosin α1 in oncology: preclinical and clinical experiences
Garaci E, Pica F, Matteucci C · 2015
View study[2][3]Safety and efficacy of Thymosin α1 in the treatment of hepatitis B virus-related acute-on-chronic liver failure
Chen JF, Chen SR, Lei ZY · 2022
View study[4][5]Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients
Clinical Trial NCT04428008 · 2023
View study[6]Thymalfasin for the treatment of chronic hepatitis B
Iino S, Toyota J, Kumada H, et al. · 2004
Cited in: Dosing
View studyThymosin Beta-46 studies
View page[1]Thymosin β4: A multifunctional immunoregulatory and tissue-repair peptide
Sosne G, et al. · 2016
Cited in: Dosing
View study[2]Thymosin β4 in tissue repair and regeneration: Activin A signaling
Metcalfe JC, et al. · 2015
View study[3][4][5]0.1% RGN-259 (Thymosin beta-4) Ophthalmic Solution Promotes Healing in Neurotrophic Keratopathy: a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial
Sosne G, Ousler GW, et al. · 2022
Cited in: Dosing
View study[6]A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 (RGN-352) for Treating Acute Myocardial Infarction
RegeneRx Biopharmaceuticals (NCT01311518) · 2011
Cited in: Dosing
View studyThymulin (FTS)4 studies
View page[1]Physiology and therapeutic potential of the thymic peptide thymulin
Bach JF, et al. · 2014
Cited in: Dosing
View study[2]Thymulin promotes Th1 differentiation and IFN-γ production in aging T cells
Fabris N, et al. · 2017
View study[3][4]Thymulin supports immune recovery during infection and chemotherapy
Dardenne M, et al. · 2018
View studyThymulin Analog (PAT)5 studies
View page[1]Targeting inflammatory components in neuropathic pain: The analgesic effect of thymulin related peptide
Safieh-Garabedian B, et al. · 2019
View study[2]Involvement of alpha-7 nicotinic acetylcholine receptors in the anti-inflammatory action of PAT
Safieh-Garabedian B, et al. · 2013
View study[3][4]A thymulin analogue peptide with powerful inhibitory effects on pain of neurogenic origin
Saadé NE, et al. · 2003
View study[5]Potent analgesic and anti-inflammatory actions of a novel thymulin-related peptide in the rat
Safieh-Garabedian B, et al. · 2002
View studyTirzepatide5 studies
View page[1]Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN et al. · 2022
Cited in: Dosing
View study[2]Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)
Frías JP, Davies MJ, Rosenstock J, et al. · 2021
View study[3]Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3)
Wadden TA, Chao AM, Machineni S, et al. · 2023
View study[4]Effects of Tirzepatide on Cardiometabolic Risk Factors
Sattar N, McGuire DK, Pavo I, et al. · 2022
View study[5]MOUNJARO (tirzepatide) injection, for subcutaneous use - FDA Prescribing Information
Eli Lilly and Company · 2025
Cited in: Dosing
View studyTripeptide-296 studies
View page[1]Gly-Pro-Hyp as a potent anti-photoaging peptide: effects on UV-induced photoaging in collagen hydrolysate studies
Yang D, et al. · 2024
Cited in: Dosing
View study[2]Pharmacokinetics of collagen tripeptide Gly-Pro-Hyp: oral bioavailability and tissue distribution
Won J, et al. · 2024
View study[3]Oral collagen hydrolysate leads to transportation of Gly-Pro-Hyp into the bloodstream and skin
Yazaki M, et al. · 2017
View study[4]Low-molecular-weight collagen peptide improves hydration, elasticity, and wrinkling: randomized double-blind placebo-controlled study
Kim DU, et al. · 2018
View study[5]Bioactive collagen hydrolysates enhance facial skin moisture and elasticity: randomized double-blind placebo-controlled trial
Inoue N, et al. · 2016
View study[6]Oral Intake of Low-Molecular-Weight Collagen Peptide Improves Hydration, Elasticity, and Wrinkling in Human Skin: A Randomized, Double-Blind, Placebo-Controlled Study
Kim DU, Chung HC, Choi J, Sakai Y, Lee BY · 2018
Cited in: Dosing
View studyTriptorelin6 studies
View page[1]Triptorelin associated adverse events evaluated using FAERS pharmacovigilance data
Jia W, Wang T · 2025
View study[2]A 6-month sustained-release formulation of triptorelin for locally advanced or metastatic prostate cancer: a real-world experience in Asia
Yee CH, Chung YH, Ko IC · 2025
View study[3]Resources Utilization Assessment and Cost-Minimization Analysis of the 6-Monthly Formulation of Triptorelin in the Treatment of Prostate Cancer in China
Chen Y, Pan J, Zhong Y · 2024
View study[4]Comparative Cardiovascular Safety of Gonadotropin-releasing Hormone Antagonists and Agonists Among Patients Diagnosed with Prostate Cancer
Patel S, Zhu K, Dave CV · 2025
View study[5]TRELSTAR (triptorelin pamoate) for injectable suspension — FDA Prescribing Information
Verity Pharmaceuticals / U.S. Food and Drug Administration · 2023
Cited in: Dosing
View study[6]TRIPTODUR (triptorelin) for extended-release injectable suspension — FDA Prescribing Information
Azurity Pharmaceuticals / U.S. Food and Drug Administration · 2022
Cited in: Dosing
View studyUlaritide6 studies
View page[1]Randomized double-blind clinical studies of ularitide and other vasoactive substances in acute decompensated heart failure: a systematic review and meta-analysis
Mitrovic V, Forssmann WG, Schnitker J · 2018
View study[2]Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies
Anker SD, Ponikowski P, Mitrovic V, Peacock WF, Filippatos G · 2015
View study[3]New Pharmacotherapeutic Classes for the Management of Heart Failure: A Narrative Review
Haryani A, Sangwan A · 2024
View study[4]Short-Term Therapies for Treatment of Acute and Advanced Heart Failure-Why so Few Drugs Available in Clinical Use, Why Even Fewer in the Pipeline?
Pollesello P, Ben Gal T, Bettex D · 2019
View study[5]Efficacy of pharmacologic therapies in patients with acute heart failure: A network meta-analysis
Dai H, Li H, Wang B · 2022
View study[6]Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure (TRUE-AHF)
Packer M, O'Connor C, McMurray JJV, et al. · 2017
Cited in: Dosing
View studyUrocortin7 studies
View page[1]Corticotropin-Releasing Hormone Family and Their Receptors in the Cardiovascular System
Takefuji M, Murohara T · 2019
View study[2]Do urocortins have a role in treating cardiovascular disease?
Chatzaki E, Kefala N, Drosos I · 2019
View study[3]Effects of Urocortin 2 Versus Urocortin 3 Gene Transfer on Left Ventricular Function and Glucose Disposal
Giamouridis D, Gao MH, Lai NC · 2018
View study[4]Urocortin-2 improves right ventricular function and attenuates pulmonary arterial hypertension
Adão R, Mendes-Ferreira P, Santos-Ribeiro D · 2018
View study[5][6]Urocortin-2 Infusion in Acute Decompensated Heart Failure: Findings From the UNICORN Study
Chan WYW, Frampton CM, Crozier IG, Troughton RW, Richards AM · 2013
Cited in: Dosing
View study[7]Cardiovascular effects of urocortin 2 and urocortin 3 in patients with chronic heart failure
Stirrat CG, Venkatasubramanian S, Pawade T, et al. · 2016
Cited in: Dosing
View studyVentfort6 studies
View page[1][2]Bioregulatory Peptides and Vascular Wall Remodeling
Khavinson VK, Linkova NS, Ryzhak GA · 2014
View study[3]KE peptide regulates SIRT1, PARP1, PARP2 gene expression and protein synthesis in human mesenchymal stem cells aging
Khavinson VK, Linkova NS, Ashapkin VV · 2023
View study[4]Molecular Aspects of Anti-aging Effect of Short Peptides
Khavinson VK, Linkova NS, Tarnovskaya SI · 2021
View study[5]Peptide Bioregulation of Aging: Results and Prospects
Khavinson VK, Linkova NS, Pronyaeva VE · 2022
View study[6]Ventfort (A-3) Blood Vessel Peptide Bioregulator — product and dosing reference
Firma Vita / St. Petersburg Institute of Bioregulation and Gerontology · 2024
Cited in: Dosing
View studyVesilute6 studies
View page[1]The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19
Linkova N, Khavinson V, Diatlova A · 2023
View study[2]Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides
Ashapkin V, Khavinson V, Shilovsky G · 2020
View study[3]Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro
Lin'kova NS, Drobintseva AO, Orlova OA · 2016
View study[4]Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's Disease
Khavinson VK, Lin'kova NS, Umnov RS · 2021
View study[5][6]Vesilute (ED dipeptide) bioregulator — dosing and protocol reference
Peptide Database (Khavinson urogenital bioregulator reference) · 2024
Cited in: Dosing
View studyVilon6 studies
View page[1]KE peptide regulates SIRT1, PARP1, PARP2 gene expression and protein synthesis in human mesenchymal stem cells aging
Khavinson VK, Linkova NS, Ashapkin VV · 2023
View study[2]The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19
Linkova N, Khavinson V, Diatlova A · 2023
View study[3]Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line
Avolio F, Martinotti S, Khavinson VK · 2022
View study[4]Peptide Regulation of Gene Expression and Protein Synthesis in Organotypic Cultures
Khavinson VK, Linkova NS, Kvetnoy IM · 2013
View study[5]Effects of short peptides on thymocyte blast transformation and signal transduction along the sphingomyelin pathway
Khavinson VKh, Rybakina EG, Malinin VV · 2002
View study[6]Vilon Peptide (KE): Bioregulator dosing and protocol overview
Project Biohacking (Khavinson bioregulator reference) · 2024
Cited in: Dosing
View studyVIP (Vasoactive Intestinal Peptide)6 studies
View page[1]IV Vasoactive Intestinal Peptide (Aviptadil) in COVID-19 Respiratory Failure: 60-Day RCT Results
Youssef JG, et al. · 2022
View study[3]Therapeutic potential of VIP and its receptor VPAC2 in type 2 diabetes
Hou X, et al. · 2022
View study[4]Therapeutic potential of VIP and its receptors in neurological disorders
White CM, et al. · 2010
View study[5]Vasoactive intestinal peptide: a potential target for antiviral therapy
He Y, et al. · 2022
View study[6]Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure (NCT04311697)
NeuroRx Inc. / Relief Therapeutics; ClinicalTrials.gov · 2020
Cited in: Dosing
View study[7]Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension
Petkov V, Mosgoeller W, Ziesche R, et al. · 2003
Cited in: Dosing
View studyXenin-255 studies
View page[1]Xenin-Derived Peptides: Multifaceted Regulators and Therapeutic Innovations in Metabolic Diseases
Gong B, et al. · 2025
View study[2]Xenin and Related Peptides: Potential Therapeutic Role in Diabetes and Related Metabolic Disorders
Craig SL, et al. · 2021
View study[3]Individual and combined effects of GIP and xenin on differentiation, glucose uptake and lipolysis in 3T3-L1 adipocytes
English A, et al. · 2020
View study[4]The methionine aminopeptidase 2 inhibitor, TNP-470, enhances the antidiabetic properties of sitagliptin in mice by upregulating xenin
Craig SL, et al. · 2021
View study[5]Xenin-25 Amplifies GIP-Mediated Insulin Secretion in Humans With Normal and Impaired Glucose Tolerance but Not Type 2 Diabetes
Wice BM, Reeds DN, Tran HD, et al. · 2012
Cited in: Dosing
View studyZiconotide (Prialt)6 studies
View page[1]Efficacy and safety of Cav2.2 blocker Ziconotide in pain: meta-analysis and systematic review
Picañol J, et al. · 2025
View study[2]Can Ziconotide Be Used to Replace Opioids? Clinical Experience in 5 Patients
Canovas Martínez L, et al. · 2025
View study[3]Selecting Neuromodulation Devices For Chronic Pain Conditions: A Narrative Review
Wahezi S, et al. · 2026
View study[4]Ziconotide as an Opioid Rescue: Economic, Clinical, and Subgroup Considerations
Gan H, et al. · 2025
View study[5][6]PRIALT (ziconotide intrathecal infusion) Prescribing Information
TerSera / U.S. FDA · 2023
Cited in: Dosing
View study